USRE44733E1 - 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block - Google Patents

6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block Download PDF

Info

Publication number
USRE44733E1
USRE44733E1 US13/432,742 US200013432742A USRE44733E US RE44733 E1 USRE44733 E1 US RE44733E1 US 200013432742 A US200013432742 A US 200013432742A US RE44733 E USRE44733 E US RE44733E
Authority
US
United States
Prior art keywords
per
cyclodextrin
deoxy
thio
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/432,742
Inventor
Mingiang Zhang
Ronald Palin
Jonathan Bennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Merck Sharp and Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8241767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE44733(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme BV filed Critical Merck Sharp and Dohme BV
Priority to US13/432,742 priority Critical patent/USRE44733E1/en
Assigned to MERCK SHARP & DOHME B.V. reassignment MERCK SHARP & DOHME B.V. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: ORGANON BIOSCIENCES NEDERLAND B.V.
Assigned to ORGANON BIOSCIENCES NEDERLAND B.V. reassignment ORGANON BIOSCIENCES NEDERLAND B.V. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: MSD OSS B.V.
Application granted granted Critical
Publication of USRE44733E1 publication Critical patent/USRE44733E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to 6-mercapto-cyclodextrin derivatives, to their use for the preparation of a medicament for the reversal of drug-induced neuromuscular block, and to a kit for providing neuromuscular block and its reversal.
  • NMBA neuromuscular blocking agent
  • anaesthesia is routinely used during the administration of anaesthesia to facilitate endotracheal intubation and to allow surgical access to body cavities, in particular the abdomen and thorax, without hindrance from voluntary or reflex muscle movement.
  • NMBAs are also used in the care of critically-ill patients undergoing intensive therapy, to facilitate compliance with mechanical ventilation when sedation and analgesia alone have proved inadequate, and to prevent the violent muscle movements that are associated with electroconvulsive therapy treatment.
  • NMBAs are divided into two categories: depolarizing and non-depolarizing.
  • Depolarizing neuromuscular blocking agents bind to nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction in a way similar to that of the endogenous neurotransmitter acetylcholine. They stimulate an initial opening of the ion channel, producing contractions known as fasciculations.
  • nAChRs nicotinic acetylcholine receptors
  • Non-depolarizing neuromuscular blocking agents compete with acetylcholine for binding to muscle nAChRs, but unlike depolarizing NMBAs, they do not activate the channel. They block the activation of the channel by acetylcholine and hence prevent cell membrane depolarization, and as a result, the muscle will become flaccid. Most of the clinically-used NMBAs belong to the non-depolarizing category. These include tubocurarine, atracurium, (cis) atracurium, mivacurium, pancuronium, vecuronium, rocuronium and rapacuronium (Org 9487).
  • a reversal agent of NMBAs is often given to the patient to assist the recovery of muscle function.
  • Most commonly used reversal agents are inhibitors of acetylcholinesterase (AChE), such as neostigmine, edrophonium and pyridostigmine. Because the mechanism of action of these drugs is to increase the level of acetylcholine at the neuromuscular junction by inhibiting the breakdown of acetylcholine, they are not suitable for reversal of depolarizing NMBAs such as succinylcholine.
  • AChE acetylcholinesterase
  • AChE inhibitors as reversal agents leads to problems with selectivity, since neurotransmission to all synapses (both somatic and autonomic) involving the neurotransmitter acetylcholine is potentiated by these agents. This non-selectivity may lead to many side-effects due to the non-selective activation of muscarinic and nicotinic acetylcholine receptors, including bradycardia, hypotension, increased salivation, nausea, vomiting, abdominal cramps, diarrhoea and bronchoconstriction.
  • these agents can be used only after or together with the administration of atropine (or glycopyrrolate) to antagonize the muscarinic effects of acetylcholine at the muscarinic receptors in the autonomic parasympathetic neuro-effector junctions (e.g. the heart).
  • atropine or glycopyrrolate
  • mAChR muscarinic acetylcholine receptor
  • atropine causes a number of side-effects, e.g., tachycardia, dry mouth, blurred vision, difficulties in emptying the bladder and furthermore may affect cardiac conduction.
  • a further problem with anticholinesterase agents is that residual neuro-muscular activity must be present (>10% twitch activity) to allow the rapid recovery of neuromuscular function.
  • NMBAs can cause complete and prolonged block of neuromuscular function (“profound block”).
  • profound block At present, there is no reliable treatment to reverse such a ‘profound block’.
  • Attempts to overcome a ‘profound block’ with high doses of AChE inhibitors has the risk of inducing a “cholinergic crisis”, resulting in a broad range of symptoms related to enhanced stimulation of nicotinic and muscarinic receptors.
  • an AChE inhibitor and a mAChR antagonist e.g., atropine
  • the chemical chelators may further be safely employed for the reversal of ‘profound block’.
  • Examples of such chemical chelators as disclosed in EP 99,306,411, were selected from various classes of, mostly cyclic, organic compounds which are known for their ability to form inclusion complexes with various organic compounds in aqueous solution, e.g. cyclic oligosaccharides, cyclophanes, cyclic peptides, calixarenes, crown ethers and aza crown ethers.
  • cyclic molecules containing six or more ⁇ -D-glucopyranose units linked at the 1,4 positions by ⁇ -linkages as in amylose, and derivatives thereof were identified in EP 99306411 as particularly useful in the reversal of many of the commonly used neuromuscular blocking agents, or muscle relaxants, such as rocuronium, pancuronium, vecuronium, rapacuronium, mivacurium, atracurium, (cis) atracurium, succinylcholine and tubocurarine.
  • 6-mercapto-cyclodextrin derivatives do belong to the main aspect of the present invention which relates to the use of a 6-mercapto-cyclodextrin derivative according to the general formula I for the manufacture of a medicament for the reversal of drug-induced neuromuscular block.
  • the invention relates to 6-mercapto-cyclodextrin derivatives having the general formula I,
  • (C 1-6 )alkylene as used in the definition of formula I means a branched or straight chain bivalent carbon radical containing 1-6 carbon atoms, such as methylene, ethylene (1,2-ethandiyl), propylene (1-methyl-1,2-ethanediyl), 2-methyl-1,2-ethanediyl, 2,2-dimethyl-1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl and 1,6-hexanediyl.
  • phenylene means a bivalent moiety the free valencies of which can be positioned either ortho, meta or para to one another.
  • (C 1-3 )alkyl means a branched or straight chain alkyl group containing 1-3 carbon atoms, i.e. methyl, ethyl, propyl and isopropyl.
  • carboxyphenyl means a phenyl group which is substituted at either the ortho-, the meta- or the para-position with a carboxy-group.
  • the ortho-carboxyphenyl group is preferred.
  • 6-mercapto-cyclodextrin derivatives of the invention are particularly preferred.
  • the 6-mercapto-cyclodextrin derivatives of formula I can be prepared by reacting a C6-activated cyclodextrin derivative of formula II with an alkylthiol, arylalkylthiol or arylthiol derivative corresponding to H—S—R—X, wherein R and X have the meaning as previously defined, in the presence of an inorganic or organic base.
  • 6-mercapto-cyclodextrin derivatives of formula I can also be prepared by reacting a 6-thiol ⁇ - or ⁇ -cyclodextrin derivative of formula III with an alkylating agent, e.g., alkyl halide, arylalkyl halide, alkyl sulfonate, arylalkyl sulfonate, corresponding to Y—X—R, wherein Y, X and R have the meanings as previously defined, or with a double bond containing reagent, e.g., vinyl alkane, acrylate, etc., or an epoxide in the presence of an inorganic or organic base.
  • an alkylating agent e.g., alkyl halide, arylalkyl halide, alkyl sulfonate, arylalkyl sulfonate, corresponding to Y—X—R, wherein Y, X and R have the meanings as
  • salts of 6-mercapto-cyclodextrin derivatives of formula I wherein X represents the carboxylic acid group COOH, the sulphonic acid group SO 2 OH, the, phosphonic acid group PO(OH) 2 or the tetrazol-5-yl group may be obtained by treating the acid with an organic base or a mineral base, like sodium-, potassium- or lithium hydroxide.
  • the 6-mercapto-cyclodextrin derivatives, or pharmaceutically acceptable salts or solvates thereof, for use in the invention are administered parenterally.
  • the injection route can be intravenous, subcutaneous, intradermal, intramuscular, or intra-arterial.
  • the intravenous route is the preferred one.
  • the exact dose to be used will necessarily be dependent upon the needs of the individual subject to whom the medicament is being administered, the degree of muscular activity to be restored and the judgement of the anaesthetist/critical-care specialist.
  • Exfracorporal application of the chemical chelators of the invention for instance by mixing of the chemical chelator with the blood during dialysis or during plasmapheresis, is also contemplated.
  • kits for providing neuromuscular block and its reversal comprising (a) a neuromuscular blocking agent, and (b) a 6mercapto-cyclodextrin derivative according to general formula I capable of forming a guest-host complex with the neuromuscular blocking agent.
  • a kit according to the invention is meant a formulation, which contains separate pharmaceutical preparations, i.e. the neuromuscular blocking agent and a 6-mercapto-cyclodextrin derivative of formula I, i.e. the reversal agent.
  • the components of such a kit of parts are to be used sequentially, i.e.
  • the neuromuscular blocking agent and a 6-mercapto-cyclodextrin derivative of formula I i.e. the reversal agent.
  • the components of such a kit of parts are to be used sequentially, i.e. the neuromuscular blocking agent is administered to a subject in need thereof, which is followed, at a point in time when restoration of muscle function is required, by the administration of the reversal agent, i.e. a 6-mercapto-cyclodextrin derivative of the present invention.
  • a preferred kit contains a 6-mercapto-cyclodextrin derivative of formula I and a neuromuscular blocking agent which is selected from the group consisting of rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, atracurium, (cis)atracurium, tubocurarine and suxamethonium.
  • a particularly preferred kit of the invention comprises rocuronium as the neuromuscular blocking agent.
  • the 6-mercapto-cyclodextrin derivatives can be applied in the form of a solution, e.g. for use as an injection preparation.
  • the pharmaceutical composition may be presented in unit-dose or multi-dose containers, for example sealed vials and ampoules, and may be stored in a freeze dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, water prior to use.
  • the invention further includes a pharmaceutical formulation, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
  • Triphenylphosphine (30.1 g, 15 eq) was dissolved with stirring in dry DMF (160 ml). To this was added iodine (30.5 g, 15.6 eq) over 10 min. with heat evolved. Dry ⁇ -cyclodextrin (10 g, 7.7 mmol) was then added and the mixture was heated to 70° C. for 24 h. The mixture was allowed to cool, to which sodium methoxide (3.1 g sodium in 50 ml methanol) was added and the mixture was stirred for 30 min, before pouring onto methanol (800 ml) and evaporating to dryness.
  • sodium methoxide 3.1 g sodium in 50 ml methanol
  • the solution was poured into acetone (500 ml) and the precipitate was collected by filtration, dissolved in water (20 ml) and dialysed (MWCO 1000) by changing the external water four times. Internal solution was evaporated to low volume and poured into acetone (250 ml). The solid precipitate was collected by filtration and dried under vacuum at 70° C.
  • 3-Mercaptopropionic acid (1.22 ml, 14.0 mmol) was dissolved in dry DMF (45 ml) under N 2 at room temperature. To this solution was added in three portions sodium hydride (1.23 g, 30.8 mmol, 60%) and the mixture was stirred for a further 30 min. To this mixture was then added dropwise a solution of 6-per-deoxy6-per-iodo- ⁇ -cyclodextrin (3.12 g, 1.40 mmol) in 45 ml dry DMF. After addition, the reaction mixture was heated at 70° C. for 12 h.
  • Per-6-mercapto- ⁇ -cyclodextrin (1 g, 0.7 mmol; see example 17) was dissolved in DMF (10 ml) and stirring commenced at room temperature under a nitrogen atmosphere.
  • N-(2-Bromoethyl)phthalimide (1.57 g, 6.17 mmol) and caesium carbonate (2 g, 6.17 mmol) were added and the resultant suspension was stirred at 60° C. overnight under a nitrogen atmosphere. After cooling to room temperature the DMF was removed in vacuo and water (100 ml) was added with vigorous stirring. The precipitate was isolated by filtration, washed with water ( ⁇ 3) and dried in vacuo to yield 1.67 g of a cream solid.
  • the solid formed was collected by filtration, dissolved in water (500 ml) and dialysed (MWCO 1000) changing the external water four times.
  • the internal solution was evaporated to low volume and then re-crystallised from hot water to afford the title compound (8.5 g) as white cross-shaped crystals.
  • the solid formed was collected by filtration, dissolved in water (200 ml) and dialysed (MWCO 1000), changing the external water four times.
  • the internal solution was evaporated to low volume and poured onto ethanol (100 ml).
  • the precipitate was collected by filtration and dried under vacuum to afford the title compound (0.55 g) as a white solid.
  • mice Male Dunkin-Hartley guinea pigs (bodyweight: 600-900 g) were anaesthetized by i.p. administration of 10 mg/kg pentobarbitone and 1000 mg/kg urethane. After tracheotomy, the animals were artificially ventilated using a Harvard small animal ventilator. A catheter was placed into the carotid artery for continuous monitoring of arterial blood pressure and the taking of blood samples for blood gas analysis. Heart rate was derived from the blood pressure signal. The sciatic nerve was stimulated (rectangular pulses of 0.5 ms duration at 10 s (0.1 Hz) intervals at a supramaximal voltage, using a Grass S88 Stimulator) and the force of M.
  • gastrocnemius contractions was measured using a Grass FT03 force-displacement transducer. Contractions, blood pressure and heart rate were recorded on a multichannel Grass 7D recorder. Catheters were placed in both jugular veins. One catheter was used for the continuous infusion of a neuromuscular blocking agent. The infusion rate of the neuromuscular blocking agent was increased until a steady-state block of 85-90% was obtained. The other catheter was used for administration of increasing doses of the reversal agent. During continuous infusion of the neuromuscular blocking agent, single doses of increasing concentration of reversal agent were given.

Abstract

Disclosed is a 6-mercapto-cyclodextrin derivative having general formula (I) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C1-6)alkylene, optionally substituated with 1-3 OH groups, or (CH2)o-phenylene-(CH2)p-; o and p are independently 0-4; X is COOH, CONHR1, NHCOR2, SO2OH, PO(OH)2, O(CH2-CH2-O)q-H, OH or tetrazol-5-yl; R1 is H or (C1-3)alkyl; R2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block.

Description

This is a National Stage filing under 35 USC 371 of PCT/EP00/11789, filed Nov. 23, 2000.
The invention relates to 6-mercapto-cyclodextrin derivatives, to their use for the preparation of a medicament for the reversal of drug-induced neuromuscular block, and to a kit for providing neuromuscular block and its reversal.
A neuromuscular blocking agent (NMBA, also called a muscle relaxant) is routinely used during the administration of anaesthesia to facilitate endotracheal intubation and to allow surgical access to body cavities, in particular the abdomen and thorax, without hindrance from voluntary or reflex muscle movement. NMBAs are also used in the care of critically-ill patients undergoing intensive therapy, to facilitate compliance with mechanical ventilation when sedation and analgesia alone have proved inadequate, and to prevent the violent muscle movements that are associated with electroconvulsive therapy treatment.
Based on their mechanisms of action, NMBAs are divided into two categories: depolarizing and non-depolarizing. Depolarizing neuromuscular blocking agents bind to nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction in a way similar to that of the endogenous neurotransmitter acetylcholine. They stimulate an initial opening of the ion channel, producing contractions known as fasciculations. However, since these drugs are broken down only relatively slowly by cholinesterase enzymes, compared to the very rapid hydrolysis of acetyl-choline by acetylcholinesterases, they bind for a much longer period than acetylcholine, causing persistent depolarization of the end-plate and hence a neuromuscular block. Succinylcholine (suxamethonium) is the best known example of a depolarizing NMBA.
Non-depolarizing neuromuscular blocking agents compete with acetylcholine for binding to muscle nAChRs, but unlike depolarizing NMBAs, they do not activate the channel. They block the activation of the channel by acetylcholine and hence prevent cell membrane depolarization, and as a result, the muscle will become flaccid. Most of the clinically-used NMBAs belong to the non-depolarizing category. These include tubocurarine, atracurium, (cis) atracurium, mivacurium, pancuronium, vecuronium, rocuronium and rapacuronium (Org 9487).
At the end of surgery or a period of intensive care, a reversal agent of NMBAs is often given to the patient to assist the recovery of muscle function. Most commonly used reversal agents are inhibitors of acetylcholinesterase (AChE), such as neostigmine, edrophonium and pyridostigmine. Because the mechanism of action of these drugs is to increase the level of acetylcholine at the neuromuscular junction by inhibiting the breakdown of acetylcholine, they are not suitable for reversal of depolarizing NMBAs such as succinylcholine. The use of AChE inhibitors as reversal agents leads to problems with selectivity, since neurotransmission to all synapses (both somatic and autonomic) involving the neurotransmitter acetylcholine is potentiated by these agents. This non-selectivity may lead to many side-effects due to the non-selective activation of muscarinic and nicotinic acetylcholine receptors, including bradycardia, hypotension, increased salivation, nausea, vomiting, abdominal cramps, diarrhoea and bronchoconstriction. Therefore in practice, these agents can be used only after or together with the administration of atropine (or glycopyrrolate) to antagonize the muscarinic effects of acetylcholine at the muscarinic receptors in the autonomic parasympathetic neuro-effector junctions (e.g. the heart). The use of a muscarinic acetylcholine receptor (mAChR) antagonist such as atropine causes a number of side-effects, e.g., tachycardia, dry mouth, blurred vision, difficulties in emptying the bladder and furthermore may affect cardiac conduction.
A further problem with anticholinesterase agents is that residual neuro-muscular activity must be present (>10% twitch activity) to allow the rapid recovery of neuromuscular function. Occasionally, either due to hyper-sensitivity of the patient or accidental overdose, administration of NMBAs can cause complete and prolonged block of neuromuscular function (“profound block”). At present, there is no reliable treatment to reverse such a ‘profound block’. Attempts to overcome a ‘profound block’ with high doses of AChE inhibitors has the risk of inducing a “cholinergic crisis”, resulting in a broad range of symptoms related to enhanced stimulation of nicotinic and muscarinic receptors.
In European Patent Application 99,306,411 (AKZO NOBEL N.V.) the use of chemical chelators (or sequestrants) as reversal agents has been disclosed. Chemical chelators capable of forming a guest-host complex for the manufacture of a medicament for the reversal of drug-induced neuromuscular block were described. The use of chemical chelators as reversal agents for NMBAs has the advantage that they are effective in reversing the action of both depolarizing and non-depolarizing NMBAs. Their use does not increase the level of acetylcholine and therefore they produce fewer side effects and none associated with the stimulation of muscarinic and nicotinic receptors seen with the AChE reversal agents. In addition, there is no need for the combined use of an AChE inhibitor and a mAChR antagonist (e.g., atropine), while the chemical chelators may further be safely employed for the reversal of ‘profound block’. Examples of such chemical chelators, as disclosed in EP 99,306,411, were selected from various classes of, mostly cyclic, organic compounds which are known for their ability to form inclusion complexes with various organic compounds in aqueous solution, e.g. cyclic oligosaccharides, cyclophanes, cyclic peptides, calixarenes, crown ethers and aza crown ethers.
The cyclodextrins,
Figure USRE044733-20140128-C00002
a class of cyclic molecules containing six or more α-D-glucopyranose units linked at the 1,4 positions by α-linkages as in amylose, and derivatives thereof, were identified in EP 99306411 as particularly useful in the reversal of many of the commonly used neuromuscular blocking agents, or muscle relaxants, such as rocuronium, pancuronium, vecuronium, rapacuronium, mivacurium, atracurium, (cis) atracurium, succinylcholine and tubocurarine.
It has now been found that 6-mercapto-cyclodextrin derivatives having the general formula I
Figure USRE044733-20140128-C00003
    • wherein m is 0-7 and n is 1-8 and m+n=7 or 8;
    • R is (C1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH2)o-phenylene-(CH2)p—;
    • o and p are independently 0-4;
    • X is COOH, CONHR1, NHCOR2, SO2OH, PO(OH)2, O(CH2—CH2—O)q—H, OH or tetrazol-5-yl;
    • R1 is H or (C1-3)alkyl;
    • R2 is carboxyphenyl;
    • q is 1-3;
      or pharmaceutically acceptable salts thereof;
      are highly active in vivo in the reversal of the action of neuromuscular blocking agents.
No protection per se is sought for the following 6-mercapto-cyclodextrin derivatives:
    • 6-per-deoxy-6-per-(2-hydroxyethylthio)-β-cyclodextrin and
    • 6-per-deoxy-6per-(2-hydroxyethylthio)-γ-cyclodextrin, which are described by Ling, C. and Darcy, R. (J. Chem. Soc. Chem Comm. 1993, (2), 203-205);
    • 6-mono-deoxy-6-mono-(2-hydroxyethylthio)-β-cyclodextrin, which is disclosed by Fujita, K. et al. (Tetr. Letters 21, 1541-1544, 1980);
    • 6-per-deoxy-6-per-(carboxymethylthio)-β-cyclodextrin, which is described by Guillo, F. et al. (Bull Chem. Soc. Chim. Fr. 132 (8), 857-866, 1995);
    • 6-mono-deoxy-6-mono-(carboxymethylthio)-β-cyclodextrin, which is described by Akiie, T. et al. (Chem. Lett. 1994 (6), 1089-1092);
    • 6A,6B-dideoxy-6A,6B-bis[(o-carboxyphenyl)thio]-β-cyclodextrin and 6A,6B-dideoxy-6A,6B-bis (carboxymethylthiol)-β-cyclodextrin, which are described by Tubashi, I. et al. (J. Am. Chem. Soc. 108, 4514-4518, 1986; and
    • 6-per-deoxy-6-per-(2,3dihydroxypropylthio)-β-cyclodextrin, which is described by Baer, H. H. and Santoyo-González, F. (Carb. Res. 280, 315-321, 1996). These prior art 6-mercapto-cyclodextrin derivatives have been described in relation with different utilities in each instance.
However, the above mentioned prior art 6-mercapto-cyclodextrin derivatives do belong to the main aspect of the present invention which relates to the use of a 6-mercapto-cyclodextrin derivative according to the general formula I for the manufacture of a medicament for the reversal of drug-induced neuromuscular block.
In one embodiment the invention relates to 6-mercapto-cyclodextrin derivatives having the general formula I,
    • wherein m is 0-7 and n is 1-8 and m+n=7 or 8;
    • X is COOH, OH or CONHCH3;
    • R is (C1-6)alkylene or (CH2)o-phenylene-(CH2)p;
    • o and p are independently 0-4; or a pharmaceutically acceptable salt thereof, with the exclusion of
      • 6-per-deoxy-6-per-(2-hydroxyethylthio)-β-cyclodextrin;
      • 6-mono-deoxy-6-mono-(2-hydroxyethylthio)-β-cyclodextrin;
      • 6-per-deoxy-6-per-(2-hydroxyethylthio)-γ-cyclodextrin;
      • 6-per-deoxy-6-per-(carboxymethylthio)-β-cyclodextrin;
      • 6-mono-deoxy-6-mono-(carboxymethylthio)-β-cyclodextrin;
      • 6A,6B-dideoxy-6A,6B-bis[(o-carboxyphenyl)thio]-β-cyclodextrin; and
      • 6A,6B-dideoxy-6A,6B-bis(carboxymethylthiol)-β-cyclodextrin.
The term (C1-6)alkylene as used in the definition of formula I means a branched or straight chain bivalent carbon radical containing 1-6 carbon atoms, such as methylene, ethylene (1,2-ethandiyl), propylene (1-methyl-1,2-ethanediyl), 2-methyl-1,2-ethanediyl, 2,2-dimethyl-1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl and 1,6-hexanediyl.
The term phenylene means a bivalent moiety the free valencies of which can be positioned either ortho, meta or para to one another.
The term (C1-3)alkyl means a branched or straight chain alkyl group containing 1-3 carbon atoms, i.e. methyl, ethyl, propyl and isopropyl.
The term carboxyphenyl means a phenyl group which is substituted at either the ortho-, the meta- or the para-position with a carboxy-group. The ortho-carboxyphenyl group is preferred.
Compounds according to formula I wherein n+m is 7 are derivatives of β-cyclodextrin, those wherein n+m is 8 are derived from γ-cyclodextrin.
Preferred are the 6-mercapto-cyclodextrin derivatives of formula I wherein X is COOH, or a pharmaceutically acceptable salt thereof.
More preferred are the 6-mercapto-γ-cyclodextrin derivatives of formula I wherein n is 8, R is (C1-6)alkylene and X is COOH.
Particularly preferred 6-mercapto-cyclodextrin derivatives of the invention are
    • 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin;
    • 6-per-deoxy-6-per-(3-carboxypropyl)thio-γ-cyclodextrin;
    • 6-per-deoxy-6-per-(4-carboxyphenyl)thio-γ-cyclodextrin;
    • 6-per-deoxy-6-per-(4-carboxyphenylmethyl)thio-γ-cyclodextrin;
    • 6-per-deoxy-6-per-(2-carboxypropyl)thio-γ-cyclodextrin; and
    • 6-per-deoxy-6-per-(2-sulfoethyl)thio-γ-cyclodextrin.
The 6-mercapto-cyclodextrin derivatives of formula I can be prepared by reacting a C6-activated cyclodextrin derivative of formula II with an alkylthiol, arylalkylthiol or arylthiol derivative corresponding to H—S—R—X, wherein R and X have the meaning as previously defined, in the presence of an inorganic or organic base.
Figure USRE044733-20140128-C00004
Formula TI wherein m is 0-7, n is 1-8, m+n=7 or 8 and Y is a leaving group which can be a halide (Cl, Br or I), sulfuric ester or a sulfonic ester function, such as a tosylate, a napthtalenesulfonate or a triflate.
Conversely the 6-mercapto-cyclodextrin derivatives of formula I can also be prepared by reacting a 6-thiol γ- or β-cyclodextrin derivative of formula III with an alkylating agent, e.g., alkyl halide, arylalkyl halide, alkyl sulfonate, arylalkyl sulfonate, corresponding to Y—X—R, wherein Y, X and R have the meanings as previously defined, or with a double bond containing reagent, e.g., vinyl alkane, acrylate, etc., or an epoxide in the presence of an inorganic or organic base.
Figure USRE044733-20140128-C00005
Formula III wherein m is 0-7, n is 1-8, m+n=7 or 8.
Alternative synthesis routes for the preparation of the 6-mercapto-cyclodextrin derivatives of the invention are known to the skilled person. The chemistry of the derivatisation of cyclodextrins is well documented (see for example: Comprehensive Supramolecular Chemistry, Volumes 1-11, Atwood J. L., Davies J. E. D., MacNicol D. D., Vogtle F., eds; Elsevier Science Ltd., Oxford, UK, 1996).
Pharmaceutically acceptable salts of 6-mercapto-cyclodextrin derivatives of formula I wherein X represents the carboxylic acid group COOH, the sulphonic acid group SO2OH, the, phosphonic acid group PO(OH)2 or the tetrazol-5-yl group, may be obtained by treating the acid with an organic base or a mineral base, like sodium-, potassium- or lithium hydroxide.
The 6-mercapto-cyclodextrin derivatives, or pharmaceutically acceptable salts or solvates thereof, for use in the invention are administered parenterally. The injection route can be intravenous, subcutaneous, intradermal, intramuscular, or intra-arterial. The intravenous route is the preferred one. The exact dose to be used will necessarily be dependent upon the needs of the individual subject to whom the medicament is being administered, the degree of muscular activity to be restored and the judgement of the anaesthetist/critical-care specialist. Exfracorporal application of the chemical chelators of the invention, for instance by mixing of the chemical chelator with the blood during dialysis or during plasmapheresis, is also contemplated.
In a further aspect the invention relates to a kit for providing neuromuscular block and its reversal comprising (a) a neuromuscular blocking agent, and (b) a 6mercapto-cyclodextrin derivative according to general formula I capable of forming a guest-host complex with the neuromuscular blocking agent. With a kit according to the invention is meant a formulation, which contains separate pharmaceutical preparations, i.e. the neuromuscular blocking agent and a 6-mercapto-cyclodextrin derivative of formula I, i.e. the reversal agent. The components of such a kit of parts are to be used sequentially, i.e. the neuromuscular blocking agent and a 6-mercapto-cyclodextrin derivative of formula I, i.e. the reversal agent. The components of such a kit of parts are to be used sequentially, i.e. the neuromuscular blocking agent is administered to a subject in need thereof, which is followed, at a point in time when restoration of muscle function is required, by the administration of the reversal agent, i.e. a 6-mercapto-cyclodextrin derivative of the present invention.
A preferred kit, according to the invention, contains a 6-mercapto-cyclodextrin derivative of formula I and a neuromuscular blocking agent which is selected from the group consisting of rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, atracurium, (cis)atracurium, tubocurarine and suxamethonium. A particularly preferred kit of the invention comprises rocuronium as the neuromuscular blocking agent.
Mixed with pharmaceutically suitable auxiliaries and pharmaceutically suitable liquids, e.g. as described in the standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, Part 8: Pharmaceutical Preparations and Their Manufacture; see especially Chapter 84 on “Parenteral preparations”, pp. 1545-1569; and Chapter 85 on “Intravenous admixtures”, pp. 1570-1580) the 6-mercapto-cyclodextrin derivatives can be applied in the form of a solution, e.g. for use as an injection preparation.
Alternatively, the pharmaceutical composition may be presented in unit-dose or multi-dose containers, for example sealed vials and ampoules, and may be stored in a freeze dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, water prior to use.
The invention further includes a pharmaceutical formulation, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
The invention is illustrated in the following examples.
EXAMPLE 1 6-mono-Deoxy-6-mono-(4-carboxyphenyl)thio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00006
To a round bottom flask containing pyridine (120 ml) was added dry γ-cyclodextrin (2.0 g, 1.54 mmol) under nitrogen at room temperature. After dissolution, 2-napthalenesulfonyl chloride (1.05 g, 4.64 mmol) in pyridine (20 ml) was added and the mixture stirred for 24 h. Quenched with water (50 ml) and evaporated to dryness to leave crude 6-mono-O-(2′-naphthalenesulfonyl)-γ-cyclodextrin.
Sodium hydride (0.38 g, 15.83 mmol) was suspended in dry dimethylformamide (20 ml). 4-Mercaptobenzoic acid (0.7 g, 4.55 mmol) was then added to the suspension and the resulting mixture was stirred for 20 minutes. γ-Cyclodextrin nosylate (3.2 g, 2.12 mmol) was added to the mixture and the reaction was heated to 100° C. for 90 minutes. After cooling, acetone was added to precipitate a solid, which was reprecipitated from water/acetone. This was then dissolved in water (20 ml), pH adjusted to 7.0 by adding 2N hydrochloric acid, then chromatographed on a Sephadex DEAE A-25 column. Appropriate fractions were combined, dialysed, then precipitated, twice from water/acetone to give 400 mg of the titled compound. 1H NMR in DMSO δ 7.4 to 7.8 (ArH), 5.0 to 5.2 (8H), 4.13 (1H), 3.7 to 4.0 (29H), 3.7 to 3.4 (17H), 3.25 (1H) ppm. 13C NMR in DMSO δ 129.9 and 127.5 (ArC), 103.3 and 102.9 (C1 and C1′), 85.0 (C4′), 81.6 (C4), 73.8 (C3), 73.5 (C2), 72.2 (C5), 70.8 (C5′), 60.6 (C6), 34.3 (C6′) ppm. Electrospray MS [M+H]+=1455.7 and [M+Na]+=1477.7.
EXAMPLE 2 6mono-Deoxy-6-mono-(2-carboxyphenyl)thio-γ-cyclodextin, Sodium Salt
Figure USRE044733-20140128-C00007
Sodium hydride (60% dispersed in oil, 0.18 g, 4.5 mmol) was added to thiosalicylic acid (0.34 g, 2.2 mmol) in DMF (25 ml) in one portion and stirred at room temperature for 30 min. To this was then added the crude solution of 6-mono-O-(2′-naphthalenesulfonyl)-γ-cyclodextrin (2.5 g, 1.45 mmol) in DMF (15 ml) and heated to 70° C. for 24 h. The mixture was cooled and quenched with water (20 ml) before evaporating to dryness. Water was then added to the residue and the resulting solution was poured into acetone (250 ml) to effect precipitation. The resulting solid was collected by filtration and dissolved in water (10 ml) before passing through a Sephadex DEAE A-25 column eluting with water then 0.2 N NaOH. Fractions containing the product were combined and evaporated to a low volume and dialysed (MWCO 1000) by changing the external water four times. Internal solution was evaporated to low volume and poured into acetone (100 ml). Solid was collected by filtration and dried under vacuum at 70° C. to leave the title compound (235 mg) as a white solid. 1H NMR (D2O) δ 7.50-7.10 (4H, m, Ar—H), 5.14 (8H, m, CyD 1-H), 4.16 (1H, m, CyD 5-H), 3.98-3.85 (26H, m, CyD 3,5,2,4-H), 3.70-3.61 (20H, m, CyD 2,3,4,6-H), 3.15 (1H, m, CyD 6-H) ppm; Electrospray MS m/z 1477.6 for [M+Na]+, calcd for C55H83NaO41S M 1455.304.
EXAMPLE 3 6-Per-deoxy-6-per-(3-carboxyphenyl)thio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00008
Triphenylphosphine (30.1 g, 15 eq) was dissolved with stirring in dry DMF (160 ml). To this was added iodine (30.5 g, 15.6 eq) over 10 min. with heat evolved. Dry γ-cyclodextrin (10 g, 7.7 mmol) was then added and the mixture was heated to 70° C. for 24 h. The mixture was allowed to cool, to which sodium methoxide (3.1 g sodium in 50 ml methanol) was added and the mixture was stirred for 30 min, before pouring onto methanol (800 ml) and evaporating to dryness. To the residue was added water (500 ml) and the solid was collected by filtration and washed with water (3×100 ml), then acetone (3×100 ml), and dried under vacuum at 70° C. to give 6-per-deoxy-6-per-iodo-γ-cyclodextrin as a yellow solid (16.2 g) which was used without further purification.
To a solution of 3-mercaptobenzoic acid (1.0 g, 10 eq) in DMF (30 ml) was added 60% sodium hydride dispersed in oil (476 mg, 22 eq) portionwise over 30 min. The mixture was cooled and 6-per-deoxy-6-per-iodo-γ-cyclodextrin (1.4 g) in DMF (30 ml) was added. The mixture was then stirred at 70° C. for 24 h. The mixture was allowed to cool to room temperature and quenched with the addition of water (20 ml) before evaporating to a low volume. The solution was poured into acetone (500 ml) and the precipitate was collected by filtration, dissolved in water (20 ml) and dialysed (MWCO 1000) by changing the external water four times. Internal solution was evaporated to low volume and poured into acetone (250 ml). The solid precipitate was collected by filtration and dried under vacuum at 70° C. to afford the title compound (1.45 g) as a white solid: 1H NMR (D2O) δ 7.77 (8H, br s, Ar—H), 7.55 (8H, d, J=6.0 Hz, Ar—H), 7.71 (16H, m, Ar—H), 5.16 (8H, s, CyD 1-H), 4.00-3.94 (16H, m, CyD 3,5-H), 3.58-3.53 (16H, m, CyD 4,2-H), 3.43-3.40 (8H, m, CyD 6-H), 3.24-3.20 (8H, m, CyD 6-H); Electrospray m/z 1190.6 for [M−8Na+6H]2−, calcd for C104H104Na8O48S8 M 2562.39.
EXAMPLE 4 6-Per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00009
3-Mercaptopropionic acid (1.22 ml, 14.0 mmol) was dissolved in dry DMF (45 ml) under N2 at room temperature. To this solution was added in three portions sodium hydride (1.23 g, 30.8 mmol, 60%) and the mixture was stirred for a further 30 min. To this mixture was then added dropwise a solution of 6-per-deoxy6-per-iodo-γ-cyclodextrin (3.12 g, 1.40 mmol) in 45 ml dry DMF. After addition, the reaction mixture was heated at 70° C. for 12 h. After cooling, water (10 ml) was added to the mixture and the volume was reduced to 40 ml in vacuo, to which ethanol (250 ml) was added resulting in precipitation. The solid precipitate was collected by filtration and dialysed for 36 h. The volume was then reduced to 20 ml in vacuo. To this was added ethanol, and the precipitate was collected by filtration and dried to give the title compound as a white solid (1.3 g, 43%). 1H-NMR D2O δ 2.47-2.51 (m, 16H); 2.84-2.88 (m, 16H); 3.00-3.02 (t, 8H); 3.11-3.14 (t, 8H); 3.62-3.68 (m, 16H); 3.92-3.97 (m, 8H); 4.04-4.06 (m, 8H); 5.19 (m, 8H) ppm. MS FIA +ion at 2024.9 m/z.
EXAMPLE 5 6-Per-deoxy-6-per-(5-carboxypentyl)thio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00010
The title compound was prepared in a similar way as described for Example 4 by reacting 6-mercaptohexanoic acid (1.34 g, 0.90 mmol) with 6-per-deoxy-6-per-iodo-γ-cyclodextrin. 1H-NMR D2O δ 1.40 (s, 16H); 1.57-1.64 (m, 32H); 2.17-2.21 (m, 16H); 2.67-3.00 (m, 16H); 2.85-2.90 (m, 8H); 3.15-3.20 (m, 8H); 3.52-3.59 (m, 8H); 3.60-3.63 (m, 8H); 3.87-3.93 (m, 16H); 5.16 (s, 8H) ppm. MS FIA +ions at 2362.2, 2213, 2065 and 1919 m/z.
EXAMPLE 6 6-Per-deoxy-6-per-(3carboxypropyl)thio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00011
The title compound was prepared in a similar way as described for Example 4 by reacting 4-mercaptobutyric acid (1.10 g, 0.009 mol) with 6-per-deoxy-6-per-iodo-γ-cyclodextrin. 1H-NMR D2O δ 1.87-1.88 (m, 16H); 2.27-2.30 (m, 16H); 2.67-2.71 (m, 16H); 2.98-3.00 (m, 8H); 3.13-3.16 (m, 8H); 3.61-3.63 (m, 16H); 3.94-4.03 (m, 16H); 5.21 (s, 8H) ppm. MS FIA +ion at 2138.8 m/z.
EXAMPLE 7 6-Per-deoxy-6-per-carboxymethylthio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00012
Sodium hydride (60% dispersion, 0.34 g, 8.60 mmol) was added to a stirred solution of ethyl 2-mercaptoacetate (0.92 ml, 8.40 mmol) in DMF (20 ml) under nitrogen at room temperature. After effervescence had ceased (15 min), per-6-deoxy-per-6-iodo-γ-cyclodextrin (2.17 g, 1.00 mmol) was added to the system. After a further 5 min, the temperature was raised to 70° C. and the reaction was left with stirring for 17 h. After cooling, DMF was removed in vacuo. Methanol (50 ml) was added and a creamy white solid slowly crystallised out of solution. This was filtered off under suction, washed with methanol and dried to give 6-per-deoxy-6-per-carbethoxymethylthio-γ-cyclodextrin as a solid (1.74 g, 82%). δH (d6-dmso) 4.95-4.85 (8H, m, 8×anomeric CH), 4.05 (16H, q, 8×CH 2CH3), 3.85-3.75 (8H, m), 3.60-3.50 (8H, m), 3.40-3.20 (32H, bs, 8×CH2SCH2), 3.20-3.10 (8H, m), 2.95-2.85 (8H, m), 1.20 (24H, t, 8×CH2CH 3).
To 1 M solution of sodium hydroxide (7 ml) was added 6-per-deoxy-6-per-carbethoxymethylthio-γ-cyclodextrin (1.00 g, 0.47 mmol) and the reaction was allowed to stir at room temperature. After 18 h, the clear solution was dialysed for 8 h, with water (2 L) being replaced every 2 h. After this time, the contents of the dialysis tubing was emptied into a flask and water evaporated in vacuo, giving the title compound as a white solid (0.62 g, 64%). δH (D2O) 5.21 (8H, d, 8×anomeric CH), 4.18-4.05 (8H, m), 4.00 (8H, dd), 3.78 (8H, dd), 3.70 (8H, dd), 3.40 (16H, dd), 3.20 (8H, d), 3.02 (8H, dd). δC (D2O) 178.1, 101.6, 82.8, 73.0, 72.7, 71.8, 39.0, 34.1 LC/MS TOF 1889 m/z.
EXAMPLE 8 6-Per-deoxy-6-per-(4-carboxyphenyl)thio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00013
To a solution of 4-mercaptobenzoic acid (856 mg) in DMF (30 ml) was added 60% sodium hydride dispersed in oil (372 mg) portionwise over 30 min. The mixture was cooled and per-6-deoxy-per-6-bromo-γ-cyclodextrin (1.0 g) was added in one portion and the mixture was stirred at 70° C. for 24 h. The mixture was allowed to cool to room temperature and quenched with the addition of water (20 ml) before evaporating to a low volume. The solution was poured into ethanol (250 ml) and the precipitate was collected by filtration, dissolved in water (20 ml) and dialysed (MWCO 1000) by changing the external water four times. Internal solution was evaporated to low volume and poured into acetone (250 ml). The solid precipitate was collected by filtration and dried under vacuum at 70° C. to afford the title compound (1.2 g) as a white solid. 1H NMR (D2O, 343K) δ 7.70 (16H, d, J=8.1 Hz, Ar—H), 7.23 (16H, d, J=7.3 Hz, Ar—H), 5.15 (8H, s, CyD 1-H), 4.00-3.96 (16H, m, CyD 3,5-H), 3.55-3.53 (24H, m, CyD 6′,4,2-H), 3.15 (8H, m, CyD 6-H); MALDI-TOF m/z 2383.7 for [M−Na8+H6], calcd for C104H104Na8O48S8 M 2562.39.
EXAMPLE 9 6-Per-deoxy-6-per-(4-carboxymethylphenyl)thio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00014
To a solution of 4-mercaptophenylacetic acid (10 eq) in DMF (50 ml) was added 60% sodium hydride in oil (22 eq) portionwise over 30 min. The mixture was cooled and per-6-deoxy-per-6-bromo-γ-cyclodextrin (1.0 g) was added in one portion and the mixture was stirred at 70° C. for 24 h. The mixture was allowed to cool to room temperature and quenched with the addition of water (20 ml) before evaporating to a low volume. The solution was then poured into acetone (250 ml) and the precipitate was collected by filtration, suspended in water (20 ml) and dialysed (MWCO 1000) by changing the external water four times. Internal solution was evaporated to low volume and poured into acetone (250 ml). The solid precipitate was collected by filtration and dried under vacuum at 70° C. to afford the title compound (1.44 g) as a white solid. 1HNMR (D2O, 343K) δ 7.15 (16H, d, J=8.0 Hz, Ar—H), 6.99 (16H, d, J=8.0 Hz, Ar—H), 4.98 (8H, s, CyD 1-H), 3.90-3.72 (16H, m, CyD 3,5-H), 3.51-3.43 (16H, m, CyD 4,2-H), 3.28 (24H, m, CH2—Ar, CyD 6′-H), 3.15-3.10 (1H, m, CyD 6-H); MALDI-TOF m/z 2495.8 for [M−Na8+H6], calcd for C112H120Na8O48S8 M 2674.6.
EXAMPLE 10 6-Per-deoxy-6-per(3-amidopropyl)thio-γ-cyclodextrin
Figure USRE044733-20140128-C00015
To a mixture of 6-per-deoxy-6-per-thio-γ-cyclodextrin (500 mg; prepared as described in Example 17) and potassium iodide (5 mg) in DMF (10 ml) was added 4-chlorobutamide (673 mg; Fries et. al. Biochemistry 1975, 14, 5233). Caesium carbonate (1.8 g) was added and the reaction mixture was heated to 60° C. overnight. The resulting mixture was poured into acetone, filtered, washed with ethanol and water and then dried in-vacuo (118 mg; 16.2%). 1H NMR (DMSO/D2O) δ 4.9 (1H, s), 3.8 (1H, m), 3.6 (1H, m), 3.4 (2H, m), 3.05 (1H, m), 2.85 (1H, m), 2.2 (2H, m), 1.75 (2H, m). Electrospray Mass Spectrum M−H (m/z) 2105.
EXAMPLE 11 6-Per-deoxy-6-per(5-hydroxy-3-oxa-pentyl)thio-γ-cyclodextrin
Figure USRE044733-20140128-C00016
2-(2-Mercaptoethoxy)ethanol (1.4 g, 11.6 mmol) was dissolved in DMF (20 ml) and stirring commenced at room temperature under a nitrogen atmosphere. Per-6-bromo-γ-cyclodextrin (2 g, 1.12 mmol) and caesium carbonate (3.2 g, 9.86 mmol) were then added and the resultant suspension stirred at 60° C. overnight under a nitrogen atmosphere. After cooling to room temperature the suspension was poured into acetone (200 ml) and the insoluble material isolated by filtration, washed with acetone (×3) and dried in vacuo. The crude product was dissolved in de-ionised water (20 ml) and dialysed (10 h). The contents of the dialysis membrane were then concentrated in vacuo to yield 1 g of the desired product as a cream solid.
1H NMR (D2O, 400 MHz): δ 2.81-3.00 (m, 24H), 3.21-3.31 (d, 8H), 3.49 (t, 8H), 3.55-3.75 (m, 56H), 3.82 (t, 8H), 3.89 (t, 8H), 5.11 (d, 8H). ESI-MS: 2175 (M−H)−.
EXAMPLE 12 6-Per-deoxy-6-per[(2(2-carboxybenzoyl)amino) ethyl]thio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00017
Per-6-mercapto-γ-cyclodextrin (1 g, 0.7 mmol; see example 17) was dissolved in DMF (10 ml) and stirring commenced at room temperature under a nitrogen atmosphere. N-(2-Bromoethyl)phthalimide (1.57 g, 6.17 mmol) and caesium carbonate (2 g, 6.17 mmol) were added and the resultant suspension was stirred at 60° C. overnight under a nitrogen atmosphere. After cooling to room temperature the DMF was removed in vacuo and water (100 ml) was added with vigorous stirring. The precipitate was isolated by filtration, washed with water (×3) and dried in vacuo to yield 1.67 g of a cream solid. Aqueous sodium hydroxide (1M, 20 ml) was then added to the crude product (600 mg) and the resultant solution stirred at room temperature overnight under a nitrogen atmosphere. The solution was then dialysed with de-ionised water until constant pH and the contents of the dialysis membrane dried in vacuo to yield 500 mg of the desired product as a glassy solid. 1H NMR (D2O, 400 MHz): δ 2.76-2.96 (m, 24H), 3.10-3.30 (m, 8H), 3.35-3.62 (m, 32H), 3.78-3.95 (m, 16H), 5.02 (d, 8H), 7.30-7.62 (m, 32H); ESI-MS: 1477 (M−2H)2−.
EXAMPLE 13 6-Per-deoxy-6-per(2-hydroxyethyl)thio-γ-cyclodextrin
Figure USRE044733-20140128-C00018
To a stirred solution of 2-mercaptoethanol (10.85 g, 10 eq) in DMF (500 ml) under nitrogen was added 60% sodium hydride dispersed in oil (11.7 g, 21 eq) portion-wise over 30 min. The mixture was stirred at room temperature for 90 minutes. Per-6-deoxy-6-per-bromo-γ-cyclodextrin (25.0 g) was added and the mixture heated to 70° C. for 24 h. The mixture was allowed to cool to room temperature and quenched by addition of water (50 ml) before evaporating to a low volume. The residue was taken up in water (100 ml) and poured onto 1:1 methanol/acetone (500 ml). The solid formed was collected by filtration, dissolved in water (500 ml) and dialysed (MWCO 1000) changing the external water four times. The internal solution was evaporated to low volume and then re-crystallised from hot water to afford the title compound (8.5 g) as white cross-shaped crystals.
1H NMR (400 MHz; DMSO) δ 5.91 (16H, br s, 2,3-OH), 4.92 (8H, s, 1-H), 4.71 (8H, t, J 4.4 Hz, SCH2CH2OH), 3.75 [8H, t, J 8.0 Hz, 3-H (or 5-H)], 3.60-3.50 [24H, m, 5-H (or 3-H), SCH2CH2OH], 3.40-3.30 (16H, m, 4-H, 2-H), 3.08 (8H, d, J 13.6 Hz, 6-H), 2.82 (8H, dd, J 13.6, 6.8 Hz, 6-H), 2.66 (16H, t, J 6.8 Hz, SCH2CH2OH); m/z (electrospray) 1775.4 for [M−H]−, calcd for C64H112S8O40 M 1776.45.
The preparation of this compound by a similar method has been published previously: J. Chem. Soc., Chem. Commun., 203 (1993).
EXAMPLE 14 6-Per-deoxy-6-per(N-methylamidomethyl)thio-γ-cyclodextrin
Figure USRE044733-20140128-C00019
To a stirred solution of N-methyimercaptoacetamide (0.58 g, 10 eq) in DMF (30 ml) under nitrogen was added 60% sodium hydride dispersed in oil (0.22 g, 10 eq) portion-wise over 30 min. The mixture was stirred at room temperature for 30 minutes. Per-6-deoxy-6-per-bromo-γ-cyclodextrin (1.0 g) was added and the mixture heated to 60-70° C. for 48 h. The mixture was allowed to cool to room temperature and quenched by addition of water (20 ml) before evaporating to a low volume. The residual solution was poured onto ethanol (100 ml). The solid formed was collected by filtration, dissolved in water (200 ml) and dialysed (MWCO 1000), changing the external water four times. The internal solution was evaporated to low volume and poured onto ethanol (100 ml). The precipitate was collected by filtration and dried under vacuum to afford the title compound (0.55 g) as a white solid.
1H NMR (400 MHz; D2O) δ 5.29 (8H, d, J 4.0 Hz, 1-H), 4.10 (8H, br t, J 9.6 Hz, 5-H), 4.05 (8H, t, J 9.8 Hz, 3-H), 3.83 (8H, dd, J 10.0, 3.6 Hz, 2-H), 3.74 (8H, t, J 9.2 Hz, 4-H), 3.58-3.49 [16H, AB system, SCH2C(O)NHCH3], 3.36 (8H, br d, J 12.8 Hz, 6-H), 3.07 (8H, dd, J 14.0, 8.4 Hz, 6-H), 2.94 (24H, s, SCH2C(O)NHCH3); m/z (electrospray) 1991.7 for [M−H]−, calculated for C72H120N8S8O40 M 1992.54.
EXAMPLE 15 6-Per-deoxy-6-per(2-carboxypropyl)thio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00020
Sodium hydride (60% in oil) (0.44 g) was added to methyl 3-mercapto-2-methyl-propionate (1.474 g; J. Med. Chem., 1994, 1159) in dimethylformamide (25 ml). After 30 minutes per-6-deoxy-per-6-bromo-γ-cyclodextrin (2.25 g), dissolved in dimethylformamide (25 ml), was added. A crystal of sodium iodide was added and the mixture heated at 75° C. overnight. The solvent was distilled off and the residue crystallised from methanol to give the methyl ester (1.3 g). Mass spec. (M−H) 2224;
1H NMR (dmso D6): δ 1.41 (d, 24H), 2.68 (m, 16H), 2.80 (m, 16H), 3.00 (m, 8H), 3.61 (3, 24H), 3.79 (m, 8H), 4.95 (s, 8H).
This product was then stirred overnight with sodium hydroxide solution (M, 13 ml). The resulting mixture was filtered, dialysed to neutrality, and evaporated to dryness to give the title compound (1.13 g). Mass spec. (M−H) 2112; 1H NMR (D2O): δ 1.15 (d, 24H), 2.5 (m, 8H), 2.65 (m, 8H), 2.8-3.1 (m, 24H), 3.65 (16H), 4.0 (m, 16H), 5.2 (s, 8H).
EXAMPLE 16 6-Per-deoxy-6-per(3-carboxypropyl)thio-β-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00021
Per-6-deoxy-per-6-bromo-β-cyclodextrin (2.25 g), methyl-4-mercaptobutyrate (1.7 g; Tetrahedron 1998, 2652), cesium carbonate (4.24 g) and dimethylformamide (25 ml) were stirred and heated together for three days. The mixture was cooled, poured into water and filtered. The solid was washed with methanol and dried (2.1 g). This was stirred overnight with sodium hydroxide solution (M, 21 ml), filtered and the filtrate dialysed to neutrality. This was evaporated to dryness giving the title compound (1.7 g). Mass Spec. (M−H) 1848.8. 1H NMR (D2O): δ 1.75 (m, 16H), 2.15 (m, 16H), 2.6 (m, 16H), 2.85 (m, 8H), 3.05 (m, 8H), 3.55 (m, 16H) 3.87 (m, 16H), 5.07 (s, 8H).
EXAMPLE 17 6-Per-deoxy-6-per(2-sulfoethyl)thio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00022
A: Per-6-deoxy-per-6-thio-γ-cyclodextrin
Per-6-deoxy-per-6-bromo-γ-cyclodextrin (20 g), thiourea (13.5 g) and dimethylformamide (100 ml) were heated together for three days at 65° C. and then ethanolamine (20 ml) was added and heating continued for two hours. The mixture was cooled, diluted with ice water and the product separated by centrifuge. The solid was washed twice with water and dried in vacuum at 65° C. giving the thiol (7.34 g).
Mass spec. (M−H) 1424. 1H NMR (dmso D6): δ 2.82 (m, 8H), 3.20 (d, 8H), 3.35 (m, 16H), 6.65 (t, 8H), 7.75 (t, 8H), 5.0 (s, 8H).
B: 6-Per-deoxy-6-per(2-sulfoethyl)thio-γ-cyclodextrin, Sodium Salt
The above per-thiol (1 g), 2-bromoethane sulphonic acid sodium salt (1.42 g), cesium carbonate (2.2 g) and dimethylformamide (10 ml) were stirred and heated overnight at 64° C. Most of the solvent was evaporated under vacuum and the residue dissolved in water. Sodium bicarbonate solution (5% w/w, 5 ml) was added and the solution dialysed three times with water. This solution was evaporated to dryness and the residue dissolved in sodium bicarbonate solution (10 ml), dialysed and evaporated as before. This process was repeated, the resulting solid was dissolved in a small volume of water and the product precipitated with methanol. This was dissolved in water and evaporated to dryness giving the title compound (1.18 g).
1H NMR (D2O): δ 3.9 (m, 24H), 3.2 (m, 24H), 3.55-3.65 (m, 16H), 3.9 (m, 8H), 4.05 (m, 8H), 5.15 (s, 8H).
EXAMPLE 18 6-Per-deoxy-6-per(2,2-di(hydroxymethyl)-3-hydroxy-propyl)thio-γ-cyclodextin
Figure USRE044733-20140128-C00023
Per-6-deoxy-per-6-thio-γ-cyclodextrin (500 mg; Example 17), 3-bromo-2,2-dihydroxy-methylpropanol (670 mg), cesium carbonate (550 mg) and dimethyiformamide (10 ml) were heated and stirred for 35 days at 65° C. until analysis by LCMS showed conversion to the required product. The mixture was evaporated to dryness, dissolved in water, dialysed against water, evaporated to low, volume and precipitated with acetone. Drying under vacuum gave the title compound (550 mg).
Mass spec. FIA (M−H) 2369. 1H NMR (D2O): δ 2.84 (m, 16H), 3.15 (m, 8H), 3.24 (m, 8H), 3.69 (s, 64H), 3.85-4.19 (m, 16H), 5.25 (s, 8H).
EXAMPLE 19 6-Per-deoxy-6-per(3-(tetrazol-5-yl)propyl)thio-γ-cyclodextrin, Sodium Salt
Figure USRE044733-20140128-C00024
Per-6-deoxy-per-6-thio-γ-cyclodextrin (1 g), 4-bromobutyronitrile (1 g), cesium carbonate (1 g) and dimethylformamide (10 ml) were stirred together at 60° C. over the weekend. The mixture was cooled, water added and the precipitate separated by centrifuge. After washing and drying the per-butyronitrile (1.4 g) was obtained. This product (1 g), sodium azide (1.3 g), triethylamine hydrochloride (2.8 g) and dimethylformamide (13 ml) were stirred and heated together for 7 days at 100° C. The mixture was cooled, diluted with water, acidified and the precipitated filtered off. This was washed with water, sonicated with methanol, separated by centrifuge, dried and dissolved in sodium hydroxide solution (M, 10 ml), filtered and dialysed to neutrality. This solution was evaporated to dryness to give the title compound (600 mg). Mass spec. (M−2H) 1152.8.
1H NMR (D2O); δ 1.95 (m, 16H), 2.55 (m, 16H), 2.85 (m, 24H), 3.05 (d, 8H), 3.5 (m, 8H), 3.6 (m, 8H), 3.9 (m, 16H), 5.06 (s, 8H).
EXAMPLE 20 Reversal of Neuromuscular Blockade in Anaesthetized Guinea Pigs in vivo
Male Dunkin-Hartley guinea pigs (bodyweight: 600-900 g) were anaesthetized by i.p. administration of 10 mg/kg pentobarbitone and 1000 mg/kg urethane. After tracheotomy, the animals were artificially ventilated using a Harvard small animal ventilator. A catheter was placed into the carotid artery for continuous monitoring of arterial blood pressure and the taking of blood samples for blood gas analysis. Heart rate was derived from the blood pressure signal. The sciatic nerve was stimulated (rectangular pulses of 0.5 ms duration at 10 s (0.1 Hz) intervals at a supramaximal voltage, using a Grass S88 Stimulator) and the force of M. gastrocnemius contractions was measured using a Grass FT03 force-displacement transducer. Contractions, blood pressure and heart rate were recorded on a multichannel Grass 7D recorder. Catheters were placed in both jugular veins. One catheter was used for the continuous infusion of a neuromuscular blocking agent. The infusion rate of the neuromuscular blocking agent was increased until a steady-state block of 85-90% was obtained. The other catheter was used for administration of increasing doses of the reversal agent. During continuous infusion of the neuromuscular blocking agent, single doses of increasing concentration of reversal agent were given. At the end of the experiment, the measured force of muscle contractions was plotted against the concentration of reversal agent, and using regression analysis techniques, the 50% reversal concentration was calculated. Results for the reversal of the neuromuscular block, induced by the muscle relaxant rocuronium bromide (Roc), by the 6-mercapto-cyclodextrin derivatives of Examples 1-19 are presented in Table I. For comparison, the reversal activity of the parent compounds β-cyclodextrin and γ-cyclodextrin are included as well.
TABLE 1
Dose (ED50, μmol · kg−1) producing 50% reversal of steady-state
neuromuscular block in anaesthetized guinea pigs and concentration
at mamimum reversal.
% max reversal
ED50 at conc.
Compound μmol · kg−1 (μmol · kg−1)
γ-cyclodextrin (γ-CD) 4 104 (47)
β-cyclodextrin (β-CD) 20 93 (113)
6-mono-deoxy-6-mono-(4-carboxyphenyl)- 0.94 102 (8.0)
thio-γ-cyclodextrin, Na salt (example 1)
6-mono-deoxy-6-mono-(2-carboxyphenyl)- 1.30 93 (11)
thio-γ-cyclodextrin (example 2)
6-per-deoxy-6-per-(3-carboxyphenyl)thio-γ- 0.28 102 (1.28)
cyclodextrin (example 3)
6-per-deoxy-6-per-(2-carboxyethyl)thio-γ- 0.09 97 (0.53)
cyclodextrin, Na salt (example 4)
6-per-deoxy-6-per-(5-carboxypentyl)thio-γ- 0.74 78 (2.5)
cyclodextrin, Na salt (example 5)
6-per-deoxy-6-per-(3-carboxypropyl)thio-γ- 0.09 108 (0.48)
cyclodextrin, Na salt (example 6)
6-per-deoxy-6-per-carboxymethylthio-γ- 0.21 88 (1.92)
cyclodextrin, Na salt (example 7)
6-per-deoxy-6-per-(4-carboxyphenyl)thio-γ- 0.10 95 (0.48)
cyclodextrin, Na salt (example 8)
6-per-deoxy-6-per-(4-carboxyphenylmethyl)- 0.13 100 (0.50)
thio-γ-cyclodextrin, Na salt (example 9)
6-per-deoxy-6-per-(3-amidopropyl)thio-γ- 0.57 94 (33)
cyclodextrin (example 10)
6-per-deoxy-6-per-(5-hydroxy-3-oxa-pentyl)- 0.47 92 (2.1)
thio-γ-cyclodextrin (example 11)
6-per deoxy-6-per-[(2(2 carboxybenzoyl)- 0.085 95 (0.48)
amino)ethyl]-thio-γ-cyclodextrin, sodium
salt (example 12)
6-per-deoxy-6-per-(2-hydroxyethyl)thio-γ- 0.20 96 (2.0)
cyclodextrin (example 13)
6-per-deoxy-6-per-(N-methylamidomethyl)- 1.54 102 (7.3)
thio-γ-cyclodextrin (example 14)
6-per-deoxy-6-per-(2-carboxypropyl)thio-γ- 0.10 103 (0.48)
cyclodextrin, sodium salt. (example 15)
6-per-deoxy-6-per-(3-carboxypropyl)thio-β- 0.5 100 (3.2)
cyclodextrin, sodium salt (example 16)
6-per-deoxy-6-per-(2-sulfoethyl)thio-γ- 0.055 106 (1.7)
cyclodextrin, sodium salt (example 17)
6-per-deoxy-6-per-(2,2,di(hydroxymethyl)- 2.9 63 (4.9)
3-hydroxy-propyl)thio-γ-cyclodextrin
(example 18)
6-per-deoxy-6-per-(3-(tetrazol-5-yl)- 0.22 109 (1.2)
propyl)thio-γ-cyclodextrin, sodium salt
(example 19)

Claims (21)

What is claimed is:
1. A 6-mercapto-cyclodextrin derivative having the general formula I
Figure USRE044733-20140128-C00025
wherein m is 0-7 and n is 1-8 and m+n=7 or 8;
R is (C1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH2)o-phenylene-(CH2)p;
o and p are independently 0-4;
X is COOH, CONHR1, NHCOR2, SO2OH, PO(OH)2, O(CH2—CH2—O)q—H, OH or tetrazol-5-yl;
R1 is H or (C1-3)alkyl;
R2 is carboxyphenyl;
q is 1-3;
or pharmaceutically acceptable salts thereof; with the exclusion of
6-per-deoxy-6-per-(2-hydroxyethylthio)-β-cyclodextrin;
6-mono-deoxy-6-mono-(2-hydroxyethylthio)-β-cyclodextrin;
6-per-deoxy-6-per-(2-hydroxyethylthio)-γ-cyclodextrin;
6-per-deoxy-6-per-(carboxymethylthio)-β-cyclodextrin;
6-mono-deoxy-6-mono-(carboxymethylthio)-β-cyclodextrin;
6A,6B-dideoxy-6A,6B-bis((o-carboxyphenyl)thio)-β-cyclodextrin;
6A,6B-dideoxy-6A,6B-bis(carboxymethylthiol)-β-cyclodextrin and 6-per-deoxy-6-per-(2,3-dihydroxypropylthio)-β-cyclodextrin.
2. The 6-mercapto-cyclodextrin derivative according to claim 1, wherein R, m and n are defined as in claim 1 and X is COOH or SO2OH; or a pharmaceutically acceptable salt thereof.
3. The 6-mercapto-cyclodextrin derivative according to claim 1, wherein m is 0; n is 8; R is (C1-6)alkylene or (CH2)o-phenylene-(CH2)p; o and p are independently 0-4; and X is COOH or SO2OH; or a pharmaceutically acceptable salt thereof.
4. A 6-mercapto-cyclodextrin derivative according to claim 1 selected from the group consisting of:
6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin;
6-per-deoxy-6-per-(3-carboxypropyl)thio-γ-cyclodextrin;
6-per-deoxy-6-per-(4-carboxyphenyl)thio-γ-cyclodextrin;
6-per-deoxy-6-per-(4-carboxyphenylmethyl)thio-γ-cyclodextrin;
6-per-deoxy-6-per-(2-carboxypropyl)thio-γ-cyclodextrin; and
6-per-deoxy-6-per-(2-sulfoethyl)thio-γ-cyclodextrin;
or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising a 6-mercapto-cyclodextrin derivative having the general formula I
Figure USRE044733-20140128-C00026
wherein m is 0-7 and n is 1-8 and m+n=7 or 8;
R is (C1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH2)o-phenylene-(CH2)p;
o and p are independently 0-4;
X is COOH, CONHR1, NHCOR2, SO2OH, PO(OH)2, O(CH2—CH2—O)q—H, OH or tetrazol-5-yl;
R1 is H or (C1-3)alkyl;
R2 is carboxyphenyl;
q is 1-3;
or a pharmaceutically acceptable salt thereof, with the exclusion of
6-per-deoxy-6-per-(2-hydroxyethylthio)-β-cyclodextrin;
6-mono-deoxy-6-mono-(2-hydroxyethylthio)-β-cyclodextrin;
6-per-deoxy-6-per-(2-hydroxyethylthio)-γ-cyclodextrin;
6-per-deoxy-6-per-(carboxymethylthio)-β-cyclodextrin;
6-mono-deoxy-6-mono-(carboxymethylthio)-β-cyclodextrin;
6A,6B-dideoxy-6A,6B-bis((o-carboxyphenyl)thio)-β-cyclodextrin;
6A,6B-dideoxy-6A,6B-bis(carboxymethylthiol)-β-cyclodextrin and 6-per-deoxy-6-per-(2,3-dihydroxypropylthio)-β-cyclodextrin, in admixture with pharmaceutically acceptable auxilliaries.
6. A kit for providing neuromuscular block and its reversal comprising (a) a neuromuscular blocking agent, and (b) a 6-mercapto-cyclodextrin derivative according to the general formula I
Figure USRE044733-20140128-C00027
wherein m is 0-7 and n is 1-8 and m+n=7 or 8;
R is (C1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH2)o-phenylene-(CH2)p;
o and p are independently 0-4;
X is COOH, CONHR1, NHCOR2, SO2OH, PO(OH)2, O(CH2—CH2—O)q—H, OH or tetrazol-5-yl;
R1 is H or (C1-3)alkyl;
R2 is carboxyphenyl;
q is 1-3;
or a pharmaceutically acceptable salt thereof.
7. The kit according to claim 6, wherein the neuromuscular blocking agent is selected from the group consisting of rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, (cis)atracurium, tubocurarine and suxamethonium.
8. The kit according to claim 6, wherein the neuromuscular blocking agent is rocuronium.
9. A method for reversal of drug-induced neuromuscular block in a patient, which comprises parenterally administering to said patient an effective amount of a 6-mercaptocyclodextrin derivative according to the general formula I
Figure USRE044733-20140128-C00028
wherein m is 0-7 and n is 1-8 and m+n=7 or 8;
R is (C1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH2)o-phenylene-(CH2)p;
o and p are independently 0-4;
X is COOH, CONHR1, NHCOR2, SO2OH, PO(OH)2, O(CH2—CH2—O)q—H, OH or tetrazol-5-yl;
R1 is H or (C1-3)alkyl;
R2 is carboxyphenyl;
q is 1-3;
or a pharmaceutically acceptable salt thereof.
10. The kit according to claim 6, wherein the neuromuscular blocking agent is vecuronium.
11. 6-Per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin, or a pharmaceutically acceptable salt thereof.
12. 6-Per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin, sodium salt.
13. A pharmaceutical composition comprising 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically suitable auxiliary.
14. A pharmaceutical composition comprising 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin, sodium salt, and a pharmaceutically suitable auxiliary.
15. A kit for providing neuromuscular block and its reversal comprising (a) a neuromuscular blocking agent, and (b) 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin, or a pharmaceutically acceptable salt thereof.
16. A kit for providing neuromuscular block and its reversal comprising (a) a neuromuscular blocking agent, and (b) 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin, sodium salt.
17. The kit according to claim 15, wherein the neuromuscular blocking agent is selected from the group consisting of rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, (cis)atracurium, tubocurarine and suxamethonium.
18. The kit according to claim 15, wherein the neuromuscular blocking agent is rocuronium.
19. The kit according to claim 15, wherein the neuromuscular blocking agent is vecuronium.
20. A method for reversal of drug-induced neuromuscular block in a subject, which comprises parenterally administering to said subject an effective amount of 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin, or a pharmaceutically acceptable salt thereof.
21. A method for reversal of drug-induced neuromuscular block in a subject, which comprises parenterally administering to said subject an effective amount of 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin, sodium salt.
US13/432,742 1999-11-29 2000-11-23 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block Active 2027-03-30 USRE44733E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/432,742 USRE44733E1 (en) 1999-11-29 2000-11-23 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99309558 1999-11-29
EP99309558 1999-11-29
US10/148,307 US6670340B1 (en) 1999-11-29 2000-11-23 6-Mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
US13/432,742 USRE44733E1 (en) 1999-11-29 2000-11-23 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
PCT/EP2000/011789 WO2001040316A1 (en) 1999-11-29 2000-11-23 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block

Publications (1)

Publication Number Publication Date
USRE44733E1 true USRE44733E1 (en) 2014-01-28

Family

ID=8241767

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/432,742 Active 2027-03-30 USRE44733E1 (en) 1999-11-29 2000-11-23 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
US10/148,307 Ceased US6670340B1 (en) 1999-11-29 2000-11-23 6-Mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
US10/603,355 Expired - Lifetime US6949527B2 (en) 1999-11-29 2003-06-23 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/148,307 Ceased US6670340B1 (en) 1999-11-29 2000-11-23 6-Mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
US10/603,355 Expired - Lifetime US6949527B2 (en) 1999-11-29 2003-06-23 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block

Country Status (34)

Country Link
US (3) USRE44733E1 (en)
EP (1) EP1259550B1 (en)
JP (2) JP3880041B2 (en)
KR (1) KR100716524B1 (en)
CN (1) CN1188428C (en)
AR (1) AR026605A1 (en)
AT (1) ATE288450T1 (en)
AU (1) AU776536B2 (en)
BE (1) BE2008C047I2 (en)
BR (1) BRPI0015947B8 (en)
CA (1) CA2390463C (en)
CO (1) CO5251450A1 (en)
CY (1) CY2008018I1 (en)
CZ (1) CZ298206B6 (en)
DE (2) DE122008000068I2 (en)
DK (1) DK1259550T3 (en)
ES (1) ES2237496T3 (en)
FR (1) FR08C0052I2 (en)
HK (1) HK1049489A1 (en)
HU (1) HU227451B1 (en)
IL (1) IL149423A0 (en)
LU (1) LU91501I2 (en)
MX (1) MXPA02004940A (en)
NL (1) NL300356I2 (en)
NO (2) NO328790B1 (en)
NZ (1) NZ518752A (en)
PE (1) PE20010902A1 (en)
PL (1) PL203012B1 (en)
PT (1) PT1259550E (en)
RU (1) RU2260013C2 (en)
SK (1) SK286282B6 (en)
TW (1) TWI242015B (en)
WO (1) WO2001040316A1 (en)
ZA (1) ZA200203538B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019102009A1 (en) 2017-11-27 2019-05-31 Medichem, S.A. Process for the synthesis of a cyclodextrin derivative
US10385142B2 (en) 2017-01-23 2019-08-20 Scinopharm Taiwan, Ltd. Method for preparing sugammadex sodium
US10442871B2 (en) * 2017-06-22 2019-10-15 Lawrence Livermore National Security, Llc Modified cyclodextrins for the selective sequestration of fentanyl related compounds and uses thereof
US11097023B1 (en) 2020-07-02 2021-08-24 Par Pharmaceutical, Inc. Pre-filled syringe containing sugammadex
WO2021170304A1 (en) 2020-02-28 2021-09-02 Medichem, S.A. Method for drying sugammadex
US11446325B2 (en) * 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
US11845811B2 (en) 2018-09-20 2023-12-19 Natco Pharma Limited Process for the preparation of Sugammadex sodium and its novel polymorphic form

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6744471B1 (en) * 1997-12-05 2004-06-01 Olympus Optical Co., Ltd Electronic camera that synthesizes two images taken under different exposures
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
ES2269504T3 (en) * 2000-11-02 2007-04-01 Akzo Nobel N.V. USE OF COMPLEXING AGENTS WITH CORTISOL IN TABLES OF TREATMENT OF DISORDERS RELATED TO HYPERCORTISOLEMIA.
CA2543443A1 (en) 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
JP2007538112A (en) 2004-01-29 2007-12-27 ピナクル ファーマシューティカルズ β-cyclodextrin derivatives and their use against anthrax lethal toxin
DK3520779T3 (en) 2004-04-23 2022-03-21 Cydex Pharmaceuticals Inc DPI formulation containing sulfoalkyl ether cyclodextrin
AU2006211173A1 (en) 2005-01-28 2006-08-10 Pinnacle Pharmaceuticals, Inc. Beta-cyclodextrin derivatives as antibacterial agents
BRPI0520654B8 (en) 2005-10-26 2021-05-25 Cydex Pharmaceuticals Inc sulfoalkyl ether cyclodextrin compositions and process for preparing the same
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20090069412A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched sugammadex
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US7938283B2 (en) * 2008-06-20 2011-05-10 Grainpro, Inc. System and method for hermetic storage of agricultural commodities during shipping
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
CN101591402B (en) * 2009-05-05 2011-11-30 杭州奥默医药技术有限公司 6-deoxy-sulfones cyclodextrin derivatives and preparation method thereof
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
DE102010012281A1 (en) * 2010-03-22 2011-09-22 Fresenius Medical Care Deutschland Gmbh Pharmaceutical compositions containing substituted 6-deoxy-6-sulfanylcyclodextrin
CN101864003B (en) * 2010-06-11 2012-05-02 漆又毛 Synthesis method of 6-deoxy thioether amino acid cyclodextrin derivative
PL2609120T3 (en) * 2010-08-25 2016-03-31 Davuluri Ramamohan Rao Improved process for preparation of sugammadex
CN102060941B (en) 2010-11-26 2012-12-26 漆又毛 6-deoxy alpha-amino acid derivative cyclodextrin, preparation and application thereof
DK3702374T3 (en) 2012-02-15 2022-06-27 Cydex Pharmaceuticals Inc PROCEDURE FOR MAKING CYCLODEXTRIN DERIVATIVES
RU2615385C2 (en) 2012-02-28 2017-04-04 Сидекс Фармасьютикалс, Инк. Alkylated cyclodextrin compositions and processes for preparing and using the same related applications
JP5892847B2 (en) * 2012-04-27 2016-03-23 Ｄｏｗａホールディングス株式会社 Composite material of cyclodextrin and silica-containing substance, method for producing the same, and gas adsorbent
GB201211153D0 (en) * 2012-06-22 2012-08-08 Farmhispania Pharmaceutical compositions
EP2909239A4 (en) 2012-10-22 2016-06-08 Cydex Pharmaceuticals Inc Alkylated cyclodextrin compositions and processes for preparing and using the same
EP2956486B1 (en) * 2013-02-14 2020-09-30 Neuland Laboratories Ltd An improved process for preparation of sugammadex sodium
WO2015179963A1 (en) 2014-05-29 2015-12-03 Uti Limited Partnership Cyclodextrin-based polyanionic and non-ionic dendrimers
AU2014398349B2 (en) 2014-06-26 2020-08-06 Maruishi Pharmaceutical Co., Ltd. Rocuronium preparation with improved stability
CN105348412B (en) * 2014-08-22 2018-06-05 江苏恩华药业股份有限公司 A kind of purification process for the more glucose sodium that relaxes
PT3183295T (en) 2014-08-22 2023-11-03 Cydex Pharmaceuticals Inc Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
EP3939582A1 (en) 2015-03-19 2022-01-19 Cydex Pharmaceuticals, Inc. Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
CN104844732B (en) * 2015-03-27 2017-05-03 山东滨州智源生物科技有限公司 Preparation method for sugammadex sodium
AU2015390471A1 (en) * 2015-04-08 2017-11-09 John KLASSEN Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof
EP3303413A4 (en) * 2015-05-29 2019-02-06 Alaparthi, Lakshmi Prasad Processes for preparation of sugammadex and intermediates thereof
CN104922693A (en) * 2015-06-19 2015-09-23 南开大学 Anionic-type cyclodextrin and anti-cancer drug clathrate compound and preparation method
CA3001200A1 (en) * 2015-10-07 2017-04-13 Uti Limited Partnership Multifunctional polyanionic cyclodextrin dendrimers
AU2016359420B2 (en) * 2015-11-25 2020-10-01 Fresenius Kabi Ipsum S.R.L. An improved process for the preparation of sugammadex and its intermediates
AU2016359431B2 (en) * 2015-11-25 2020-10-22 Fresenius Kabi Ipsum S.R.L. Crystalline forms of per-chloro-gamma-cyclodextrines
EP3433285B1 (en) * 2016-03-22 2020-06-03 Fresenius Kabi iPSUM S.r.l. An improved process for the preparation of sugammadex
EP3448395B1 (en) * 2016-04-29 2020-04-22 Alveron Pharma B.V. Cyclodextrins as procoagulants
WO2017144734A2 (en) 2016-06-23 2017-08-31 Synthon B.V. Process for making sugammadex
US10526422B2 (en) 2016-06-29 2020-01-07 Beijing Creatron Institute Of Pharmaceutical Research Co., Ltd. Process for preparation and purification of Sugammades sodium
WO2017084401A1 (en) 2016-06-29 2017-05-26 北京睿创康泰医药研究院有限公司 Sugammadex preparation and purification method
CN107778383B (en) 2016-08-24 2020-03-10 王炳永 Refining method of sugammadex sodium
KR20190141244A (en) 2017-05-03 2019-12-23 사이덱스 파마슈티칼스, 인크. Compositions Containing Cyclodextrins and Busulfans
CN109021148B (en) * 2017-06-08 2020-11-10 天津科伦药物研究有限公司 Method for preparing sugammadex sodium
ES2761899T3 (en) 2017-06-30 2020-05-21 Synthon Bv Process to prepare Sugammadex
US10233263B1 (en) * 2017-08-23 2019-03-19 Formosa Laboratories, Inc. Method for preparation of sugammadex sodium
TWI703163B (en) * 2017-08-23 2020-09-01 台耀化學股份有限公司 Method for preparing sugammadex sodium and crystalline form thereof
CN107892727B (en) * 2017-11-27 2019-12-24 合肥博思科创医药科技有限公司 Method for purifying sugammadex sodium
US11225565B2 (en) 2018-04-06 2022-01-18 Synthon B.V. Purification of sugammadex
KR102054228B1 (en) * 2018-05-28 2019-12-10 연성정밀화학(주) Process for Preparing Sugammadex Sodium
US11634511B2 (en) 2018-06-07 2023-04-25 Merck Sharp & Dohme Llc Processes for the preparation of sugammadex
CN110615860A (en) * 2018-06-20 2019-12-27 江苏恒瑞医药股份有限公司 Method for purifying sugammadex sodium
WO2020028448A1 (en) 2018-08-02 2020-02-06 Pliva Hrvatska D.O.O. Solid state forms of sugammadex sodium
CA3112872A1 (en) 2018-09-27 2020-04-02 Werthenstein Biopharma Gmbh Novel crystalline forms of sugammadex
JP6950966B2 (en) * 2018-11-01 2021-10-13 丸石製薬株式会社 Sugamadex or its pharmacologically acceptable salt-containing liquid and its production method
CN109824800A (en) * 2018-12-29 2019-05-31 鼎元(天津)生物医药科技有限公司 A kind of preparation method of the easypro more glucose sodium of selectivity flesh pine antagonistic
CN109438591B (en) * 2018-12-29 2021-02-09 博瑞生物医药（苏州）股份有限公司 Preparation process of sugammadex sodium
US20220169753A1 (en) 2019-03-29 2022-06-02 Hospira, Inc. An improved process for preparation of sugammadex acid and sugammadex sodium
CN111978435B (en) 2019-05-22 2021-05-25 合肥博思科创医药科技有限公司 Preparation method of high-purity sugammadex sodium
US11324692B2 (en) 2019-07-03 2022-05-10 Galenicum Health S.L.U. Method to prepare pharmaceutical compositions of suggamadex
US20220273517A1 (en) 2019-08-30 2022-09-01 Terumo Kabushiki Kaisha Injection formulation
RU2724900C1 (en) * 2019-10-24 2020-06-26 Маруиси Фармасьютикал Ко., Лтд. Rocuronium preparation with improved stability
CN111019016B (en) * 2019-12-27 2022-02-18 武汉嘉诺康医药技术有限公司 Synthesis method of sugammadex impurity
CN111714459B (en) * 2020-06-18 2022-06-14 广州瑞尔医药科技有限公司 Shugeng sodium gluconate powder injection and preparation method thereof
EP3932391A1 (en) 2020-07-03 2022-01-05 Galenicum Health S.L.U. Method to prepare pharmaceutical compositions
US11945788B2 (en) 2021-06-07 2024-04-02 Nuray Chemicals Private Limited Process for preparing pitolisant hydrochloride and solid-state forms thereof
CN113637097A (en) * 2021-08-10 2021-11-12 北京恒创星远医药科技有限公司 6-full-deoxidation-6-full-iodo-gamma-cyclodextrin crystal and preparation method and application thereof
CN115708777A (en) 2021-08-19 2023-02-24 北京费森尤斯卡比医药有限公司 Packaged pharmaceutical product comprising mercaptocyclodextrin derivative or pharmaceutically acceptable salt thereof and method of preservation

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929813A (en) 1973-12-26 1975-12-30 Interx Research Corp Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and process for preparing same
US4599327A (en) 1982-12-03 1986-07-08 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt Dibenzo[bd]pyran derivatives, process for the preparation thereof and pharmaceutical compositions containing same
US4603123A (en) 1984-02-22 1986-07-29 Chiesi Farmaceutici, S.P.A. Compounds having antiinflammatory activity, obtained by complexation of piroxican with β-cyclodextrin, and pharmaceutical compositions containing them
EP0197571A2 (en) 1985-03-15 1986-10-15 Janssen Pharmaceutica N.V. Novel derivatives of gamma-cyclodextrin
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4816462A (en) 1982-05-18 1989-03-28 Nowicky Wassili Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds
US4834985A (en) 1986-06-05 1989-05-30 Euroceltique S.A. Controlled release pharmaceutical composition
US4869904A (en) 1986-12-26 1989-09-26 Nisshin Flour Milling Co., Ltd. Sustained release drug preparation
US4983636A (en) 1976-03-09 1991-01-08 Rikagaku Kenkyusho Wako Composition and method of treating selected malignant conditions
US4983586A (en) 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
US5008386A (en) 1987-10-13 1991-04-16 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Methylated cyclodextrin type compounds and process for preparing same
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
EP0447171A2 (en) 1990-03-15 1991-09-18 Tanabe Seiyaku Co., Ltd. Polysulfate of cyclodextrin derivative and process for preparing the same
WO1992000331A1 (en) 1990-06-28 1992-01-09 The United States Of America, Represented By The Secretary, United States Department Of Commerce Regioselective substitutions in cyclodextrins
EP0465535A1 (en) 1989-04-03 1992-01-15 Janssen Pharmaceutica N.V. Regioselective substitutions in cyclodextrins
US5180716A (en) 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
US5385891A (en) 1991-08-29 1995-01-31 Tanabe Seiyaku Co., Ltd. Polysulfate of β-cyclodextrin derivative and process for preparing the same
AU3662895A (en) 1994-11-04 1996-05-09 Commonwealth Scientific And Industrial Research Organisation Method for treating animals
WO1997017977A1 (en) * 1995-11-15 1997-05-22 Everest-Todd Research & Development Limited Topical compositions containing a beta-cyclodextrin and an amino polysaccharide
US5767112A (en) 1994-10-21 1998-06-16 Poli Industria Chimica, S.P.A. Muscle relaxant pharmaceutical compositions
US5834446A (en) * 1996-06-21 1998-11-10 Queen's University At Kingston Nerve process growth modulators
US5840881A (en) 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
US5935941A (en) 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
JPH11246603A (en) 1998-02-27 1999-09-14 Nippon Shokuhin Kako Co Ltd New cyclodextrin derivative and its production
WO2001012202A2 (en) 1999-08-13 2001-02-22 Akzo Nobel N.V. Use of chemical chelators as reversal agents for drug-induced neuromuscular block
WO2001040316A1 (en) 1999-11-29 2001-06-07 Akzo Nobel N.V. 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US20020111377A1 (en) 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
US20020173550A1 (en) 1998-05-29 2002-11-21 Antonio Calignano Control of pain with endogenous cannabinoids
WO2004000832A1 (en) 2002-06-21 2003-12-31 Akzo Nobel N.V. 1-[(indol-3-yl)carbonyl] piperazine derivatives
US7026304B2 (en) 2001-02-14 2006-04-11 Akzo Nobel N.V. 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block

Patent Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929813A (en) 1973-12-26 1975-12-30 Interx Research Corp Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and process for preparing same
US4983636A (en) 1976-03-09 1991-01-08 Rikagaku Kenkyusho Wako Composition and method of treating selected malignant conditions
US4816462A (en) 1982-05-18 1989-03-28 Nowicky Wassili Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds
US4599327A (en) 1982-12-03 1986-07-08 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt Dibenzo[bd]pyran derivatives, process for the preparation thereof and pharmaceutical compositions containing same
US4603123A (en) 1984-02-22 1986-07-29 Chiesi Farmaceutici, S.P.A. Compounds having antiinflammatory activity, obtained by complexation of piroxican with β-cyclodextrin, and pharmaceutical compositions containing them
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
EP0197571A2 (en) 1985-03-15 1986-10-15 Janssen Pharmaceutica N.V. Novel derivatives of gamma-cyclodextrin
US4834985A (en) 1986-06-05 1989-05-30 Euroceltique S.A. Controlled release pharmaceutical composition
US4869904A (en) 1986-12-26 1989-09-26 Nisshin Flour Milling Co., Ltd. Sustained release drug preparation
US5008386A (en) 1987-10-13 1991-04-16 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Methylated cyclodextrin type compounds and process for preparing same
US4983586A (en) 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
EP0465535A1 (en) 1989-04-03 1992-01-15 Janssen Pharmaceutica N.V. Regioselective substitutions in cyclodextrins
EP0447171B1 (en) 1990-03-15 1994-11-02 Tanabe Seiyaku Co., Ltd. Polysulfate of cyclodextrin derivative and process for preparing the same
US5250520A (en) * 1990-03-15 1993-10-05 Tanabe Seiyaku Co., Ltd. Polysulfate of cyclodextrin derivative and process for preparing the same
EP0447171A2 (en) 1990-03-15 1991-09-18 Tanabe Seiyaku Co., Ltd. Polysulfate of cyclodextrin derivative and process for preparing the same
WO1992000331A1 (en) 1990-06-28 1992-01-09 The United States Of America, Represented By The Secretary, United States Department Of Commerce Regioselective substitutions in cyclodextrins
US5180716A (en) 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
US5385891A (en) 1991-08-29 1995-01-31 Tanabe Seiyaku Co., Ltd. Polysulfate of β-cyclodextrin derivative and process for preparing the same
US5840881A (en) 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
US5767112A (en) 1994-10-21 1998-06-16 Poli Industria Chimica, S.P.A. Muscle relaxant pharmaceutical compositions
AU3662895A (en) 1994-11-04 1996-05-09 Commonwealth Scientific And Industrial Research Organisation Method for treating animals
WO1997017977A1 (en) * 1995-11-15 1997-05-22 Everest-Todd Research & Development Limited Topical compositions containing a beta-cyclodextrin and an amino polysaccharide
US5834446A (en) * 1996-06-21 1998-11-10 Queen's University At Kingston Nerve process growth modulators
US5935941A (en) 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
JPH11246603A (en) 1998-02-27 1999-09-14 Nippon Shokuhin Kako Co Ltd New cyclodextrin derivative and its production
US20020173550A1 (en) 1998-05-29 2002-11-21 Antonio Calignano Control of pain with endogenous cannabinoids
WO2001012202A2 (en) 1999-08-13 2001-02-22 Akzo Nobel N.V. Use of chemical chelators as reversal agents for drug-induced neuromuscular block
US7265099B1 (en) 1999-08-13 2007-09-04 Organon N.V. Use of chemical chelators as reversal agents for drug-induced neuromuscular block
WO2001040316A1 (en) 1999-11-29 2001-06-07 Akzo Nobel N.V. 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US6670340B1 (en) 1999-11-29 2003-12-30 Akzo Nobel 6-Mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
US20040029833A1 (en) 1999-11-29 2004-02-12 Minggiang Zhang 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US6949527B2 (en) 1999-11-29 2005-09-27 Akzo Nobel N.V. 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US20020111377A1 (en) 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
US7026304B2 (en) 2001-02-14 2006-04-11 Akzo Nobel N.V. 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
WO2004000832A1 (en) 2002-06-21 2003-12-31 Akzo Nobel N.V. 1-[(indol-3-yl)carbonyl] piperazine derivatives

Non-Patent Citations (56)

* Cited by examiner, † Cited by third party
Title
Adam, J. M., et. al; J. Med. Chem; Cyclodextrin-Derived Host Moleculaes as Reversal agents for the Neuromuscular Blocker Rocuronium Bromide: Synthesis and Structure-Activity Relationships, (2002), vol. 45, pp. 1806-1816.
Alvarez-Gomes, J.A., et al., "Reversal of vecuronium-induced shallow neuromuscular blockade is significantly faster with sugammadex compared with neostigmine", Eur. J. Anasthesiol, 2007; 24(Suppl 39); Abstract 9AP7-8.
Anderson, W.R., et al., "Brain-enhanced delivery of testosterone using a chemical delivery system complexed with 2-hydroxypropyl-b-cyclodextrin", 1997, Drug Design and Delivery, 2; 287-298.
AshtonP.R., et al., Chem. Eur. J., Synthetic Cyclic Oligosaccharides-Syntheses and Structural Properties of a Cyclo(1-4) . . . , (1986), vol. 2, No. 5, pp. 580-591.
Baer, et al., Carbohydrate Research, 280 (1996); Keptakis[6-S-(2,3-dihydroxypropyl)-6-thio] cyclomaltoheptaose and its sulfone: water-soluble B-cyclodextrin derivatives having modified polarity, pp. 315-321.
Baer, H. et al "Heptakis[6-S-(2,3-dihydroxypropyl)-6-thio]cyclomaltoheptaose . . ." Carbohyd. Res. (1996) vol. 280, pp. 315-321. *
Bisson, AP, et al., Che. Eur. J., "Cooperative Ineractions in a Ternary Mixture", (1998), vol. 4, No. 5, pp. 845-851.
Bom, A, et. al. , Angew Chem Int Ed; "A Novel Concept of Reversing Neuromuscular Block: Chemical Encapsulation of Rocuronium Bromide by a Cyclodextrin-Based Synthetic Host", (2002), vol. 41, No. 2,pp. 266-270.
Connors, K.A., Wiley Interscience, "Binding Constants. The measurement of molecular complex stability" (1987), New York, pp. 24-28.
Cram, D.J., et al., Am Chem Soc., "Macro Rings VIII. Aromatic Substitution of the (6,6) Paracyclophane", 1955, vol. 77, pp. 1179-1186.
Desire, B, et. al., Experientia; "Inactivation of sarin and soman by cyclodextrins in vitro", vol. 43, No. 4, (1987), pp. 395-397.
Desire, B. et al. "Interaction of Soman with □-Cyclodextrin1," Fundamental and Applied Toxicology, vol. 7, No. 4 (1986) pp. 646-657.
Escandar, G.M., Spectrofluorometric determination of piroxicam in the presence and absence of beta-cyclodextrin, vol. 124, No. 4, Feb. 1999, pp. 587-597: abstract medline.
Fielding, L., Determination of association constants (Ka) from Solution NMR Data, Tetrahedron 56 (2000) 6151-6170, May 2000.
Gattuso, G. et al. "Synthetic Cyclic Oligosaccharides," Chem. Rev. (1998) vol. 98, pp. 1919-1958.
Gennaro, A. R., et al., "Intravenous Admixtures" Chapter 85, Remington's Pharmaceutical Sciences, 18th Ed. Mack Publishing Company (1990) pp. 1545-1569.
Gennaro, A. R., et al., "Parental Preparations" Chapter 84, Remington's Pharmaceutical Sciences, 18th Ed. Mack Publishing Company (1990) pp. 1570-1580.
Golden, J. H. "Bi(anthracene-9,10-dimethylene) (Tetrabenzo-[2,2]-para-cyclophane].," J. Chem. Soc. (1961) pp. 3741-3748.
Guillo, et al., Bull. Chim. Soc. Fr., vol. 132, "Synthesis of Symmetrical cyclodextrin derivatives bearing multiple charges"; Jul. 4, 1995; pp. 857-866.
Guillo, F. et al "Synthesis of symmetrical cyclodextrin derivatives . . ." Bull. Soc. Chim. Fr. (1995) vol. 132, pp. 857-866. *
Hamelin, B., et al., American Chemical Society; 1995; "Formation of Highly Stable Heterodimers in Aquaeous Solution between B-Cyclodextrin Derivatives Bearing Multiple Opposite Charges"; 99, pp. 17877-17885.
Hamelin, et al., Formation of highly stable heterodimers in aqueous solution between B-cyclodextrin derivatives bearing opposite charges, J. Phys. Chem., vol. 99, No. 51, Aug. 1995.
Irie, T. et al. "Protective mechanism of □-cyclodextrin for the hemolysis induced with phenothiazine neuroleptics in vitro," J. Pharm. Dyn., vol. 6, No. 6 (1983) pp. 408-414.
Jicsinszky, L., et al., Comprehemsive Supramolecular Chemistry, vol. 3, Cyclodextrins, Elsevier Science Ltd., Oxford UK (1996) pp. 57-188.
Jones, RK, et al., "Reversal of Profound Rocuronium-induced Blockade with Sugammadex: A Rando . . .", Anesthesiology 2008: 109; 816-24.
Khan, A. R. et al. "Methods for Selective Modifications of Cyclodextrins," Chem. Rev. (1998) vol. 98, pp. 1977-1996.
Kuroda, et al; J. Chem. Soc. Perkin Trans, 1989; "Dynamic Molecular Motions of p-Methylcinnamic Acid included in B-Cyclodextrin Derivatives: A New Type of Free-energy Relationship in Complex Formation", pp. 1409-1416.
Kwak, et al, Determination of the binding of B-cyclodextrin derivatives to adamantine carboxylic acids using capillary electrophoresis, Chromatographia, vol. 43, No. 11/12, Dec. 1996.
Lee, C., et al., "Reversal of Profound Neuromuscular Block by Sugammadex Administered Three Minutes After Rocuronium", Anesthesiology, V. 110, No. 5, May 2009.
Lee, et al., Structure, Confirmation, and action of neuromuscular blocking drugs, British Journal of Anaesthesia, 87 (5): 755-69 (2001).
Lindberg, et. al., Carbohydrate Research,"Synthesis of some 2-0-(2-hydroxyalkyl) and 2-0-(2,3-di-hydroxyalkyl) derivatives of cyctomaltoheptaose", 22, 1991, pp. 113-119.
Loukas, Y. L., "Measurement of Molecular Association in Drug: Cyclodextrin Inclusion Complexes with Improved 1H NMR Studies," J. Pharm. Pharmacol (1997) vol. 49, pp. 944-948.
Luna et al., Isolation and characterization by NMR spectroscopy of three monosubstituted 4-sulfobutyl ether derivatives of cyclmaltoheptaose (B-cyclodrextrin), Carbohydrate Research 299 (1997), 111-118.
May, C. et al. "Development of a toxin-binding agent as a treatment for tunicaminyluracil toxicity: protection against tunicamycin poisoning of sheep," Australian Veterinary Journal, vol. 76, No. 11 (1998) pp. 752-756.
Miller et al., Sugammadex: An opportunity to change the practice of anesthesiology?, International Anesthesia Research Society, vol. 104, No. 3, Mar. 2007.
Miyake, M. et al. "Anionic Cyclophanes as Hosts for Cationic Aromatic Guests," Tetrahedron Letters, vol. 32, No. 49 (1991) pp. 7295-7298.
Miyake, M. et al. "Biomimetic Studies Using Artificial Systems. VI.1) Design and Synthesis of Novel Cyclophanes Having Eight Carboxyl Groups on the Aromatic Rings2)," Chem. Pharm. Bull., vol. 41(7) (1993) pp. 1211-1213.
PCT Search Report and Written Opinion for International Application No. PCT/EP00/11789 (WO2001/40316, corresponding to US6670340) dated Nov. 2, 2002; 4 pages.
Pitha, et al., Int'l Journal of Pharmaceutics, "Hydroxypropyl-B-Cyclodextrin: preparation and Characterization; effects on Solubility of Drugs", vol. 29, Issue 1, pp. 73-82 (1986).
Pitha, et al., Life Sciences, "Drug Solubilizers to Aid Pharmacologists: Amorphous Cyclodextrin Derivatives", 43: 492-502 (1988).
Richardson, JD; "Cannabinoids modulate pain by multiple mechanism of action", Journal of Pain 2000, vol. 1; No. 1; 2000; pp. 2-14.
Selected prosecution history of U.S. Appl. No. 10/049,393 (US7265099), including obviousness type double patenting rejection mailed Dec. 31, 2003, and applicant's response; and obviousness-type double patenting rejection mailed Aug. 7, 2006 and Applicant's response.
Selected prosecution history of U.S. Appl. No. 10/603,355 (US6,949,527), including obviousness type double patenting rejection mailed Feb. 8, 2005 and applicant's response filed Mar. 9, 2005.
Soga, T. et al. Modifications of Hydrophobic Cavity and their Effects on the Complex Formation with a Hydrophobic Substrate, Tetrahedron Letters, vol. 21 (1980) pp. 4351-4354.
Stella, V. J. et al. "Cyclodextrins: Their Future in Drug Formulation and Delivery," Pharmaceutical Research, vol. 14, No. 5 (1997), pp. 556-567.
Supplementary European Search Report dated Jul. 20, 2001, for related International Application No. PCT/EP00/076494.
Szente, L. et al. "Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development," Advanced Drug Delivery Reviews (1999) vol. 36, pp. 17-28.
Tarver, G. J. et al., 2-O-Substituted Cyclodextrins as Reversal Agents for the Neuromuscular Blocker Rocuronium Bromide, Bioorganic & Medicinal Chemistry (2002) vol. 10, pp. 1819-1827.
Tubashi, I, et al., Artificial Receptors for Amino Acids in Water. Local Environmental Effect on Polar Recognition by 6A,6B-dideoxy-6A,6B-bis(carboxymethylthiol)-B-Cyclodextrin, J. Am. Chem. Soc. 108, 4514-4518, 1986).
Uekama, K., et al., "Cyclodextrin Drug Carrier Systems", Chem Rev. (1998) vol. 98. pp. 2045-2076.
Uekama, K., et al., Effects of cyclodextrins on chlorpromazine-induced haemolysis and central nervous system responses:, J. Pharm. Pharmacol, vol. 33, No. 11 (1981), pp. 707-710.
Vogtle, et al. Comprehensive Supramolecular Chemistry, vol. 2, Molecular recognition: Receptors for molecular guests, Atwood et al. eds; Elsevier Science Ltd., Oxford, UK (1996) pp. 211-266.
Wenz, et al., "Synthesis of highly water-soluble cyclodextrin sulfonates by addition of hydrogen sulfite to cyclodextrin allyl ethers", Carbohydrate Research 322 (1999) 153-165.
Yaksh, T.L., et al., "Studies of pharmacology and pathology intrathecally administered 4-anilinopiperidine analogues and morphine in rat and cat," Anesthesiology, 64; 54-66. (1986).
Zarzycki, P.K., et al., The equilibrium constant of beta cyclodextrin-phenolphthalein complex: influence of temperature and tetrahydrofuran addition, vol. 18, No. 1-2, 1998, pp. 165-170.
Zhang, M.G, Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal?: Drugs of the Future (2003), vol. 28, No. 4, pp. 347-354.

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10385142B2 (en) 2017-01-23 2019-08-20 Scinopharm Taiwan, Ltd. Method for preparing sugammadex sodium
US10442871B2 (en) * 2017-06-22 2019-10-15 Lawrence Livermore National Security, Llc Modified cyclodextrins for the selective sequestration of fentanyl related compounds and uses thereof
WO2019102009A1 (en) 2017-11-27 2019-05-31 Medichem, S.A. Process for the synthesis of a cyclodextrin derivative
US11104746B2 (en) 2017-11-27 2021-08-31 Medichem, S.A. Process for the synthesis of a cyclodextrin derivative
US11845811B2 (en) 2018-09-20 2023-12-19 Natco Pharma Limited Process for the preparation of Sugammadex sodium and its novel polymorphic form
WO2021170304A1 (en) 2020-02-28 2021-09-02 Medichem, S.A. Method for drying sugammadex
US11097023B1 (en) 2020-07-02 2021-08-24 Par Pharmaceutical, Inc. Pre-filled syringe containing sugammadex
US11446325B2 (en) * 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases

Also Published As

Publication number Publication date
HUP0203755A3 (en) 2003-10-28
NZ518752A (en) 2003-03-28
CA2390463A1 (en) 2001-06-07
NL300356I1 (en) 2008-10-01
EP1259550B1 (en) 2005-02-02
NL300356I2 (en) 2009-04-01
FR08C0052I2 (en) 2009-12-18
AU5438001A (en) 2001-06-12
CY2008018I2 (en) 2009-11-04
HK1049489A1 (en) 2003-05-16
CY2008018I1 (en) 2009-11-04
JP3880041B2 (en) 2007-02-14
NO2010019I2 (en) 2012-08-27
IL149423A0 (en) 2002-11-10
DE122008000068I1 (en) 2009-04-23
AR026605A1 (en) 2003-02-19
LU91501I9 (en) 2019-01-02
US6949527B2 (en) 2005-09-27
DE122008000068I2 (en) 2011-06-16
MXPA02004940A (en) 2003-05-23
CZ20021814A3 (en) 2002-08-14
CN1188428C (en) 2005-02-09
DE60017947D1 (en) 2005-03-10
CA2390463C (en) 2009-02-03
NO328790B1 (en) 2010-05-18
NO2010019I1 (en) 2010-11-22
US20040029833A1 (en) 2004-02-12
BRPI0015947A (en) 2002-08-20
KR100716524B1 (en) 2007-05-10
DE60017947T2 (en) 2005-06-23
ZA200203538B (en) 2003-08-04
NO20022522L (en) 2002-05-28
PL203012B1 (en) 2009-08-31
BRPI0015947B1 (en) 2012-02-07
ES2237496T3 (en) 2005-08-01
CO5251450A1 (en) 2003-02-28
WO2001040316A1 (en) 2001-06-07
NO20022522D0 (en) 2002-05-28
JP2006348301A (en) 2006-12-28
HUP0203755A2 (en) 2003-04-28
HU227451B1 (en) 2011-06-28
KR20020063900A (en) 2002-08-05
SK7262002A3 (en) 2002-11-06
ATE288450T1 (en) 2005-02-15
CZ298206B6 (en) 2007-07-18
AU776536B2 (en) 2004-09-16
JP2003515623A (en) 2003-05-07
PE20010902A1 (en) 2001-09-06
SK286282B6 (en) 2008-06-06
TWI242015B (en) 2005-10-21
LU91501I2 (en) 2009-01-26
JP4563972B2 (en) 2010-10-20
PL356097A1 (en) 2004-06-14
EP1259550A1 (en) 2002-11-27
FR08C0052I1 (en) 2009-02-27
DK1259550T3 (en) 2005-04-25
PT1259550E (en) 2005-05-31
RU2260013C2 (en) 2005-09-10
CN1402737A (en) 2003-03-12
BE2008C047I2 (en) 2019-12-11
US6670340B1 (en) 2003-12-30
BRPI0015947B8 (en) 2021-07-06

Similar Documents

Publication Publication Date Title
USRE44733E1 (en) 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
US7026304B2 (en) 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US20100075938A1 (en) Use of Chemical Chelators as Reversal Agents for Drug-Induced Neuromuscular Block
EA018959B1 (en) Carboxyethylated cyclodextrin polysulfates useful as medicaments
HU226370B1 (en) Carbohydrate derivatives with antithrombotic activity and pharmaceutical compositions contg. them
US20110212907A1 (en) Hexadecasaccharides with antithrombotic activity, including a covalent bond and an amino chain

Legal Events

Date Code Title Description
AS Assignment

Owner name: ORGANON BIOSCIENCES NEDERLAND B.V., NETHERLANDS

Free format text: MERGER;ASSIGNOR:MSD OSS B.V.;REEL/FRAME:030824/0449

Effective date: 20130101

Owner name: MERCK SHARP & DOHME B.V., NETHERLANDS

Free format text: MERGER;ASSIGNOR:ORGANON BIOSCIENCES NEDERLAND B.V.;REEL/FRAME:030824/0642

Effective date: 20130102

FPAY Fee payment

Year of fee payment: 12

PTEF Application for a patent term extension

Free format text: PRODUCT NAME: BRIDION (SUGAMMADEX SODIUM); REQUESTED FOR 5 YEARS

Filing date: 20160210

Expiry date: 20210127